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CHAPTER I 
 
 
INTRODUCTION 
    
Obesity has become a major health issue in the United States and the prevalence 
has doubled in the past 30 years [1]. Parallel to the increase in obesity is a rise in obesity-
related chronic diseases such as cardiovascular disease (CVD) and diabetes.  CVD 
continues to be the leading cause of death in the United States and diabetes and obesity 
are major risk factors of CVD. In 2006, approximately 36.3% of the population in the 
United States had at least one form of CVD and 33.9% of the population had a body mass 
index (BMI) over 30 kg/m2 [2].  The death rate of CVD was 35.3% in 2005 which means 
1 out of 3 patients died of CVD [2].  The health cost associated with CVD was estimated 
to be $475.3 billion in 2008 [2]. The 2006 prevalence of physician-diagnosed prediabetes 
and diabetes was about 36.5% of the adult population [2]. The total medical cost for 
diabetes was $174 billion in 2007 [3].  
Consumption of a high fat diet and elevated blood glucose and lipids are known 
contributors to the development of diabetes and CVD [4]. Pharmacological, dietary, and 
lifestyle modifications such as regular physical activity are ways that can improve blood 
glucose and lipids. For patients with severe diabetes or hyperlipidemia, medications may 
be necessary to control the progression of these disorders.  
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 Some of the pharmacological agents used to reduce blood glucose concentration 
include α-glucosidase inhibitors (e.g. acarbose-precose), biguanide (e.g. metformin), 
thiazolidinediones (TZDs) (e.g. rosiglitazone), insulin analogs, meglitinides, and d-
phenylalanine derivatives [5]. Most of these medications mimic the function of insulin to 
treat patients with hyperglycemia [5].  Specifically, α-glucosidase inhibitors reduce the 
absorption of carbohydrates in the small intestine, preventing the elevation of blood [6]. 
Biguanide, an insulin-sensitizer, increases the uptake of glucose in peripheral tissues and 
inhibits hepatic gluconeogenesis [6]. Meglitinides and d-phenylalanine enhances insulin 
secretion while TZDs are similar to biguanide and functions as insulin sensitizers [6]. 
TZDs are agonists of peroxisome proliferator activated receptor (PPAR) -γ which up-
regulates the transcription of genes involved in adipocyte differentiation and production 
of adipokines such as adiponectin and leptin [6]. TZDs have been shown to effectively 
decrease plasma glucose and lipid concentrations in insulin-resistant patients [6]. 
Rosiglitazone is a widely used TZD and a known PPAR-γ agonist commonly used by 
patients with type 2 diabetes [7]. Although rosiglitazone modulates blood glucose 
concentrations, it is associated with side effects such as weight gain, anemia, osteoporosis 
and fluid rentention [8-9]. 
Peroxisome proliferator activated-receptors (PPARs) are a family nuclear receptor 
proteins that regulate the expression of genes involved in cellular differentiation and 
macronutrients metabolism, such as glucose and lipids [10]. PPARs initiate the 
transcription of genes involved in energy homeostasis and are also key factors in 
regulating many age-associated pathophysiological diseases related to oxidative stress 
and inflammatory reaction [10-11]. PPARs can be divided into three subtypes:  PPAR-γ, 
 3
PPAR-α, and PPAR-β/δ. PPAR-γ is primarily expressed in adipose tissue and is involved 
in the production of adipocytes and their function [12]. The activation of PPAR-γ 
improves insulin sensitivity in insulin-sensitive tissues such as the liver and adipose by 
up-regulating glucose disposal in peripheral tissues and down-regulating glucose 
production respectively [12]. PPAR-α is crucial for lipid metabolism including β-
oxidation, ketogenesis, fatty acid synthesis and lipoprotein metabolism [13]. Fenofibrate 
is known as a PPAR-α agonist and it has been used to lower cholesterol [14]. The use of 
fenofibrate is often associated with side effects including skin problems (yellow skin), 
gastrointestinal effects, muscle pain, and sweating or dizziness [15]. Rhabdomyolysis, a 
rapid lysis of skeletal muscle tissue due to tissue injury, is also seen often in elderly 
patients using fenofibrate [16].  
Because of the side effects associated with rosiglitazone and fenofibrate, other 
options are being explored for lowering blood glucose and cholesterol concentrations. 
Natural food products containing bioactive compounds are continuously being 
investigated for their potential in reducing chronic conditions such as obesity and 
diabetes [17-18]. Fruits and vegetables containing phytochemicals have been investigated 
for their health promoting properties and examples are carrot, dark green leafy 
vegetables, and apple, bluberry, and mango [19-21]. Mango is a rich source of many 
bioactive compounds [22]. It is a tropical fruit containing various bioactive components 
such as polyphenols, carotenoids, and vitamins E and C [23]. A recent study 
demonstrated that an aqueous extract of mango stem exhibited anti-inflammatory effects 
by reducing the expression of inflammation-related genes in murine macrophages [24]. 
Ojewole [25] demonstrated that mango extract effectively lowered blood glucose in 
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mouse model. The antioxidant and anti-cancer effects of mango juice had been 
demonstrated by inhibiting free radical production and neoplastic transformation in 
mammalian cell lines [26]. However, to our knowledge, there are few studies exploring 
the effect of mango on body composition and glucose and lipid parameters in diet-
induced obesity. Therefore, we hypothesize that mango contains bioactive compounds 
that can act as PPAR-α and PPAR-γ agonists resulting in modulation of body fat, and 
plasma glucose and lipid parameters in mice fed high fat diet which aims to induce 
obesity.  
The specific aims of the study are: 
1. To compare the effects of two doses of freeze-dried mango with known PPAR agonists 
(rosiglitazone and fenofibrate, PPAR-γ and PPAR-α agonist, respectively) in modulating 
body composition in mice fed high fat diet.  
2. To compare the effects of two doses of freeze-dried mango with rosiglitazone and 
fenofibrate in decreasing the elevation of blood glucose concentrations in mice fed high 
fat diet.  
3. To compare the effects of two doses of freeze-dried mango with rosiglitazone and 
fenofibrate in reducing blood lipid concentrations in mice fed high fat diet.  
4. To begin to explore the mechanism through which mango exerts positive effects on 
body composition and blood glucose and lipids. Expression of genes involved in glucose 
and lipid homeostasis will be examined in the liver, white adipose tissue, and skeletal 
muscle using quantitative Real Time-PCR. 
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Limitations 
There are several limitations to our study:  (1) only a single variety of mango 
(Tommy/Atkins) was tested and our findings may not represent all mango varieties. It has 
been shown that varietal differences occur in terms of nutrient and phenolic content [27]; 
(2) freeze-dried mango was used in the study but fresh mango may have different 
properties; (3) the dose of freeze-dried mango was based on earlier animal studies using 
dried fruit such as dried plum, blueberries, or apple for lowering blood cholesterol 
concentrations [28-30]. The doses (this is not a dose-seeking study), particularly the 10% 
mango that we used, might not be a reasonable amount for humans. However, our study 
demonstrated that the 1% dose, a very reasonable dose for humans, is effective in 
modulating body composition and blood glucose and lipid concentrations in this animal 
model; (4) the dose and mode of administration of rosiglitazone (50 mg/kg diet) and 
fenofibrate (500 mg/kg diet) used in the study may not be the most effective in 
modulating body composition and blood glucose and lipids in this animal model. The 
dose and mode of administration of rosiglitazone and fenofibrate was based on the 
findings of Chao et al [31] and Guerre-Millo et al [32], respectively; (5) Because of the 
use of an animal model, our findings need to be confirmed in humans. A clinical study 
should be conducted to determine whether the positive results we have observed in this 
study will translate to the same positive effects in humans. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Obesity and its associated diseases 
Obesity has become one of the most severe epidemics in western societies. The 
percentage of obese population has doubled in the last decade and the prevalence 
continues to increase. In the US, the estimated number of overweight or obese adults (age 
20 and older) reached 145,000,000 in 2006, representing 66.7% of the adult population 
[2]. The annual medical cost associated with obesity was $117 billion in 2001, 
accounting for over 9.1% of the U.S. health expenditure [2]. Overweight and obesity are 
caused by many factors such as increased caloric dietary intake, consumption of high fat 
diet foods, lack of physical activity, and heredity. The increased prevalence of obesity has 
given rise to many comorbid conditions such as diabetes mellitus, insulin resistance, 
dyslipidemia, hypertension, and atherosclerosis [33].  
The World Health Organization (WHO) defines overweight or obesity as 
“abnormal or excessive fat accumulation that presents a risk to health” [34]. The different 
stages of overweight or obesity are classified by body mass index (BMI), defined as 
weight (in kilograms) divided by the square of the height (in meters) 
(BMI=weight/height2) [34]. The categories of BMI were initially derived from life- 
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expectancy data collected from insurance companies, and the cut-offs match risks for 
obesity-related morbidities [35]. BMI equal to or greater than 30 kg/m2 is defined as 
“grade 2 obesity” while a BMI of > 25 kg/m2 is denoted as “overweight” or “grade 1 
obesity”. The ideal BMI is between 18.5 and 25 kg/m2. In general when a person’s BMI 
is greater than 25 kg/m2, he or she is considered overweight [36]. 
 Studies in the past decade have investigated the regulation of obesity and appetite 
which influences energy homeostasis [37-38]. In general, an abundance of adipose tissue 
in the body is necessary for survival under critical conditions such as starvation [39]. 
However, the continuation of excess energy intake when energy expenditure remains 
stable results in excessive fat storage [40-41]. Obesity can negatively modulate both lipid 
and glucose metabolism [42-43]. Obesity has been determined to play a key in the 
regulation of insulin resistance in type 2 diabetes [44].  
Adipose tissue is no longer considered only as a site for fat storage but also 
functions as an endocrine organ [45]. Adipocytes are responsible for secretion of 
adipokines which contribute to hypertension and dyslipidemia [45]. During insulin 
resistance, there was an increased adiposity and glucose intolerance seen in mice [46]. 
Recent studies have also shown that adipose tissue has the ability to secrete 
proinflammatory molecules such as tumor necrosis factor-α (TNF- α), interleukin-6 (IL-
6) and C-reactive protein-1 (CRP-1) [45]. Adipose tissue also secretes many kinds of 
adipocytokines, such as leptin and adiponectin [47]. Leptin is important in regulating 
energy balance because it inhibits dietary intake and facilitates energy expenditure [47]. 
Adiponectin has an inverse relationship with obesity and has been shown to increase 
insulin sensitivity [47]. 
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 Free fatty acids, derived from excessive stored triacylglycerol, play an important 
role in dyslipidemia and may promote the development hypertriglyceridemia by 
inhibiting lipogenesis and oxidative stress [33]. In obese subjects, excessive amounts of 
fat stimulate the release of free fatty acids and promote lipotoxicity inducing oxidative 
stress [33]. Oxidative stress is produced from lipids and their metabolites, which are not 
found only in adipose tissue but also in non-adipose tissue such as the liver and pancreas 
[48-49].   
 Excess free fatty acids are also associated with insulin-receptor dysfunction 
leading to insulin resistance, hyperglycemia, and increased hepatic gluconeogenesis. Free 
fatty acids also inhibit the use of glucose in insulin-stimulated muscle tissue which 
further exacerbates hyperglycemia [50-51]. Elevated free fatty acids also affect the 
function of pancreatic β-cell resulting in decreased insulin secretion [52]. 
Obesity is highly associated with, or is a primary contributing factor to, some of 
the more severe metabolic diseases. Reducing obesity and overweight have been shown 
to reduce the total risk and mortality of patients with coronary heart disease [53]. Obesity 
also has a direct connection with sub-clinical inflammation which is involved in the 
pathogenesis of many chronic diseases including type 2 diabetes and cardiovascular 
disease [54].  
 Treatment of obesity can be generally divided into three categories: lifestyle 
modifications, medications, or surgical. Lifestyle modifications include changing dietary 
habits and increasing physical activity. It is well-established that, consuming less calories 
and increasing energy expenditure is the key to weight loss [55]. Many weight loss diets 
are aimed at decreasing calorie intake, therefore preventing weight gain. Examples of 
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weight loss diets include the Mediterranean diet, low-carbohydrate diet, and low-fat diet. 
The Mediterranean diet is morden nutritional recommended-diet with moderate amounts 
of fat and is rich in vegetables and limited in red meat [56].  A low-carbohydrate diet, 
defined as diet programs that restrict cabohydrate intake for purposes of weight loss or 
treatment of obesity, does not have a strict calorie requirement while low-fat diet is 
similar to the Mediterranean diet but with lower fat consumption [56]. Engaging in 
regular physical activity is another aspect of lifestyle modification which increases 
energy expenditure.  
The next treatment of obesity is medications. Weight loss drugs are also being 
widely used to reduce or prevent overweight and obesity [57]. Sibutramine and Orlistat 
are two examples of effective weight loss drugs. Sibutramine, in combination with a low-
calorie diet, regulates the appetite center which is located in the hypothalamus of the 
brain causing a reduction in demand for food [58]. Some side effects of sibutramine 
include back pain, constipation, dry mouth, flu-like symptoms, headache, and nausea [59-
60]. Another weight loss medication is Orlistat which blocks the digestion and absorption 
of dietary fats [61]. Major side effects of orlistat are diarrhea, abdominal pain, 
hypertension, depression, headache and diabetic ketoacidosis [62].  
Bariatric surgery is performed in cases of severe obesity. The major types of 
bariatric surgery performed are: Roux-en-Y gastric bypass and gastric banding [63]. In 
Roux-en-Y gastric banding [64], the stomach is dissected into a small pouch with the 
proximal portion attached to the proximal jejunum, while the distal section of the 
stomach pouch and a small portion of the jejunum are connected to the distal jejunum. 
Roux-en-Y gastric bypass restricts food intake and limits nutrient absorption. Gastric 
 10
banding is a pure restrictive surgical treatment that divides the stomach into smaller and 
larger portions by use of prosthetic band. The position of the band in gastric banding can 
be adjusted to change the volume of proximal pouch [65]. The acute side effects of 
bariatric surgeries are hemorrhage, obstruction, infection, arrhythmias, and pulmonary 
emboli. Long-term adverse effects are rhabdomyolysis, neuropathies, internal hernias, 
and emotional disorders [66].  
Due to the side effects of exisiting therapies, the use of nutritional interventions is 
being widely explored for the treatment of obesity [67].  
Diabetes mellitus (DM) 
Prevelance  
 In 2006, there were approximately 57 million adults (25.9%) total in the US 
diagnosed with prediabetes, which is defined as a condition that occurs when the blood 
glucose levels are higher than the normal but not high enough to be diagnosed as diabetes 
[2]. Additionally, 7.7% (approximately 17 million) adults were diagnosed with diabetes 
in 2006. Type 2 diabetes accounted for 90-95% of the diagnosed diabetes [2].  The 
mortality due to diabetes in 2005 was about 75,119 and at least 65% of the people with 
diabetes died of some type of heart disease [2]. Diabetes mellitus is a chronic disease 
distinguished by abnormally elevated glucose level (hyperglycemia) as a result of insulin 
resistance. The chronic situation of diabetes can cause lasting dysfunction and failure of 
various organs, such as the eyes, kidneys, heart, and nerves [68]. 
 
Type 2 diabetes mellitus (T2DM) 
 T2DM is a chronic disease characterized by impaired insulin resistance and insulin 
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secretion [69]. T2DM occurs when pancreatic β-cells does not produce enough insulin or 
the body ignores insulin [70]. The impairment of insulin secretion then weakens the 
insulin response of the body to glucose [70]. Both genetics and environmental factors can 
affect development of T2DM [71].  
 Genetics influence important transcription factors such as hepatocyte nuclear factor 
and insulin promoter factor-1 which control the development and function of the β-cells 
of the pancreas [72]. About 70-85% of T1DM patients inherit the disease from their 
parents and the polygenic inheritance associates with environmental factors to develop 
diabetes [73]. Environmental factors, also known as acquired factors, such as lifestyle, 
body weight, physical activity, hypertension, dyslipidemia and smoking also play a major 
role in the development diabetes [71]. 
 Insulin secretion can be influenced by several nutrients such as glucose, some 
amino acids, and free fatty acids [74-75]. Hormones also affect the secretion of insulin 
from the pancreas. One of the stimulatory hormones is glucagon-like polypeptide-1, 
which is a candidate therapeutic agent for T2DM [76]. An example of the inhibitory 
hormones is somatostatin. Somatostatin is a peptide hormone that inhibits the release of 
numerous secondary hormones, including insulin [77]. Proinsulin is the precursor of 
insulin produced from pancreatic β-cells and cleaved into insulin and C-peptide before 
departing from the β-cells [78]. Even though proinsulin is the precursor of insulin, 
elevation of proinsulin has been observed in T2DM [78] and may be indicate of insulin 
resistance [70].  
 Insulin resistance is defined as “diminished tissue response to insulin at one or 
more sites in the complex pathways of hormone actio, and is usually heralded by higher 
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than normal plasma insulin levels, a phenomenon known as compensatory 
hyperinsulinaemia” [79]. In insulin resistance, plasma insulin levels may remain normal 
or even elevated but is insufficient to overcome hyperglycemia [73]. Hence, 
hyperinsulinemia is usually considered as an early stage insulin-resistant marker [80]. 
Several abnormalities in insulin signaling system may relate to insulin resistance, such as 
reduced insulin receptor expression and tyrosine kinase activity, which regulates signal 
transduction for regulating of enzyme activity [81]. The impaired signaling system is a 
possible explanation for decrease glucose uptake and metabolism in the liver, skeletal 
muscle, and adipocytes [80, 82-84].  
 In the liver, insulin is responsible for the inhibition of hepatic glucose formation 
during postprandial state [85]. When a tissue becomes insulin resistant, both fasting and 
postprandial glucose production increases, eventually leading to T2DM. Insulin 
resistance is recognized by a reduction in glucokinase activity and a marked elevation of 
conversion of substrates to glucose regardless of the presence of insulin [86]. Therefore, 
glucose is over-produced and under-utilized in diabetics. The increase in free circulating 
fatty acids seen in type 2 diabetics may be associated with increased hepatic glucose 
formation since non-esterified fatty acids was found to deteriorate glucose tolenrance in 
Caucasians [87]. Skeletal muscle also plays an important role in glucose metabolism. The 
role of the skeletal muscle in glucose homeostasis is as important as in the liver because 
of the large amount of glucose utilized in the skeletal muscle [84].  
 GLUT4 is the major glucose transporter present in adipose tissue and skeletal 
muscle and it is stimulated by insulin [88-89]. In the presence of insulin, GLUT4 is 
translocated to the cell membrane facilitates glucose uptake. The uptake of glucose from 
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circulation into peripheral tissues is important in glucose homeostasis since it removes 
glucose from circulation and then decreases blood glucose level. Defective insulin-
induced GLUT4 translocation is often seen in T2DM and may contribute to hyerglycemia 
[90-91].  
 Most type 2 diabetics are overweight or obese [68]. A study showed that visceral 
fat plays a negative role in insulin-resistant patients, and progress of metabolic syndrome 
was observed after surgical removal of visceral fat [92]. Goodpaster and colleagues [93] 
demonstrated that losing an appropriate amount of weight by calorie restriction increases 
insulin sensitivity and reduces total adiposity, and weight loss after one year did improve 
insulin sensitivity in type 2 dibetics [94].  
 
Prevention and treatment 
 There are several ways to prevent or delay the development of T2DM. Restricting 
calorie intake, increasing physical activities and limiting alcohol consumption are ways to 
prevent or delay the development of T2DM [95]. Once T2DM has developed, treatment 
options include taking natural products and pharmacological therapy [95].  
 Calorie restriction, defined as minimized energy intake, but sufficient intake of 
vitamins, minerals and other important nutrient, also prevents or delays the development 
of T2DM. Several studies have shown that weight loss can improve insulin sensitivity in 
skeletal muscle [93, 96-97]. It is also suggested that the surgical removal of visceral fat 
improved insulin sensitivity in hepatocytes in rodents [98]. As little as a 7% weight loss, 
type 2 diabetics improved insulin sensitivity by approximately 60% [99]. In other words, 
weight loss induced by calorie restriction prevents T2DM by promoting insulin sensitity.  
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 Another lifestyle factor that could improve insulin sensitivity is physical activity. 
Physical activity or exercise is not necessarily accompanied by weight loss; however, 
improvement in insulin sensitivity was still observed [100]. Possible explanations of 
improvement of insulin sensitivity are that GLUT4 is elevated during physical activity 
[101] and an increase in glycogen formation [102]. A weight loss associated physical 
activity study demonstrated that obesity and insulin resistance were reduced in men who 
performed exercise and on calorie restriction [97].  
 Lifestyle modifications may prevent or delay T2DM. These can be effective 
treatment options. Alcohol consumption is not recommended for type 2 diabetic patients 
because alcohol has been shown to be related with impaired glucose tolerance [103-106]. 
A recent study showed a decreased risk of T2DM in elderly women with low intake of 
alcohol [105]. Furthermore, very low to moderate amount of alcohol consumption has 
been shown to lower insulin resistance [107]; however the underlying mechanism 
remains unknown.  
 Many studies have shown that ~ 1 in 3 adults with T2DM use therapies such as 
acupuncture, chiropractic care, yoga, and herbal remedies to prevent and/or treat type 2 
DM [108-110]. In addition to these interventions, consumption of supplements such as 
chromium, garlic, ginseng and various herbal or botanical supplements, are other ways of 
preventing and/or treating T2DM [111]. Taking these supplements for the prevention 
and/or treatment of diabetes remains controversial. For example, the ability of chromium 
supplements to improve insulin sensitivity yields conflicting results and needs to be 
further examined [112]. Various therapies and consumption of supplements are being 
widely used; however pharmacological therapy is more concerned in clinical treatment of 
 15
T2DM.  
 Pharmacological therapy provides by far the most effective option in the treatment 
of T2DM. Metformin is an anti-diabetic drug that has been widely used to treat T2DM, 
particularly in overweight or obese diabetics [113]. Type 2 diabetics have a higher rate of 
glucose production than non-diabetics and metformin can effectively lower this rate by 
over 30% [114]. Metformin reduces glucose production by inhibiting hepatic 
gluconeogenesis [115]. Physiologically, metformin activates AMP-activated protein 
kinase (AMPK) which suppresses gluconeogenesis in the liver [116]. A recent study 
illustrated that activated AMPK could promote the expression of small heterodimer 
partner (SHP), a transcriptional factor that inhibits the activity of two enzymes (glucose-
6-phosphatase and fructose 1, 6-bisphosphatase) in the hepatic gluconeogenesis [117]. 
Other mechanisms by which metformin enhance insulin sensitivity includes increasing 
glucose uptake and promoting β-oxidation is rodent skeletal muscle [118].  
 Thiazolidines (TZDs), such as pioglitazone and rosiglitazone, are group of 
medications that have been commonly used in T2DM. TZDs activate PPAR-γ, resulting 
in the transcription of insulin-sensitive genes (examples are GLUT4 and aP2) involved in 
lipid and glucose metabolism in the liver, adipose tissue, and skeletal muscle [119-120]. 
Pioglitazone improves fasting plasma glucose and HbA1c, and increases insulin 
sensitivity and plasma adiponectin in T2DM subjects [121]. Pioglitazone decreases 
insulin resistance in the liver and peripheral tissues which can promote glucose uptake. 
However, heart failure is a major side effect associated with the use of TZDs [122].The 
role of rosiglitazone in reducing glucose will be discussed in a later section.  
 Pramlintide is an analog of human amylin, a pancreatic islet cell hormone released 
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from β-cells along with insulin [123]. Administration of pramlintide in type 2 diabetics 
significantly improved postprandial hyperglycemia [123-125]. Additionally, pramlintide 
is reported to exhibit a weight loss property [126] possibly thru delaying gastric emptying 
[127]. Similar to amylin, pramlintide enhances insulin sensitivity by regulating glucose 
metabolism thru modulating postpradial glucose levels [123], inhibiting glucagon 
secretion [128], and delaying gastric emptying [129].   
 Exenatide acts as a potent agonist of glucagon-like peptide-1. Exenatide enhances 
β-cell proliferation in rodents but this proliferation is not exhibited in humans [130]. 
Similar to glucagon-like peptide-1, exenatide enchances glucose-dependent insulin 
secretion by the pancreatic β-cells, inhibits glucagon secretion and decreases the both rate 
of gastric emptying and food intake, although the mechanism of action is still under 
investigation [131-133]. A two-year clinical study showed exenatide to significantly 
reduce plasma HbA1c by 1% and promote weight loss [124].  
   
Peroxisome proliferator activated receptors (PPARs) and their physiological roles 
 Peroxisome proliferator activated receptors (PPARs) belong to the super family of 
steroid nuclear receptor of transcription factors that modulate ligand-dependent activation 
and suppression of genes [134]. The binding of PPARs to specific peroxisome 
proliferator response elements (PPREs) allows them to mediate transcription for genes 
involved in lipid and glucose metabolism [135]. This property of PPARs gives them 
potential therapeutic applications as a treatment for lipid and glucose associated 
metabolic syndrome. 
 Structurally, PPAR proteins contain six domains: A/B, C, D, E and F domains. The 
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A/B domain is considered the activation site for transcription. The C domain is where 
DNA binds to the location of zinc finger. The D domain is referred to as the DNA 
sequence recognition site, and E and F domains are the sites for ligand binding [136]. The 
DNA-binding domain primarily recognizes and binds to specific response element [42]. 
PPARs form heterodimers with attachment of retinoic acid X receptor (RXR) and binds 
to PPREs in target genes [137]. Once PPARs have been activated by ligand, they are 
ready to bind to specific promoting regions that stimulate the transcription of RNA 
polymerase of target genes [137].   
Figure 1. Six domains of PPAR protein [134]: 
 
 Three types of PPARs that have been identified: PPAR-α, PPAR-β/δ, and PPAR-γ 
[138]. PPAR-α is most abundantly expressed in the liver, brown adipose tissue, kidney, 
heart and skeletal muscle; PPAR β/δ is expressed in the intestine, adipose tissue, skeletal 
muscle, heart and brain and PPAR-γ is expressed in adipose tissue and the intestine [137-
138]. The ligands for PPARs are divided by their target proteins, for example PPAR-α 
ligands can be divided into natural and synthetic groups [139]. Natural ligands for PPAR-
α include fatty acids and eicosanoids while synthetic ligands for PPAR-α are fibrates 
such as fenofibrate and bezafibrate, and nonsteroidal anti-inflammatory medications, 
such as prostaglandins. Natural ligands of PPAR-γ are fatty acid derivatives such as 
arachidonic acid metabolites [140]. Synthetic ligands of PPAR-γ are TZDs and 
nonsteroidal anti-inflammatory chemicals, such as indomethacin and ibuprofen [141]. 
Prostacylin, a natural compound produced by vascular endothelial and smooth muscle 
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cells when stimulated by cytokines, is a ligand of PPAR-β/δ [142]. 
 Transcription initiated by PPARs is responsible for the synthesis of proteins that are 
involved in various biological pathways [143]. PPAR-α spares glucose during the fasting 
state and promotes fatty acid oxidation and ketone body formation. PPAR-γ regulates 
lipid storage and glucose utilization in a fed state [12]. PPAR-β/δ is a regulator that 
enhances fatty acid catabolism in skeletal muscle [144]. The anti-inflammatory effects of 
PPAR-α and PPAR-γ are well established based on in vitro and in vivo studies [145]. For 
example, PPAR-α and PPAR-γ agonists appear to delay the initiation phase of the 
inflammatory process in paw edema model of inflammation [146]. Because the focus of 
our study is on PPAR-α and -γ, hence, PPAR-β/δ will not be discussed further.  
 PPAR-α is a direct regulator of genes that function in fatty acid uptake and 
oxidation in the liver [147]. PPAR-α null mice become dyslipidemic because 
peroxisomal and mitochondrial fatty acid metabolizing enzymes cannot metabolize long-
chain fatty acids [148-149].  Interestingly PPAR-α null mice do not develop high-fat 
diet-induced insulin resistance, but show signs of fat accumulation [150].  
 PPAR-γ ligands have been used to increase insulin sensitivity in T2DM [134]. The 
most common PPAR-γ ligands are the TZDs which include troglitazone, pioglitazone, 
and rosiglitazone [151]. Genes that are regulated by PPAR-γ are involved in maintaining 
lipid and glucose homeostasis [134]. PPAR-γ regulates glucose homeostasis by 
modulating hormones secreted from adipocytes [143, 152]. Thus, PPAR-γ is an insulin 
sensitizing factor and regulates of the expression of adipokines, such as increasing 
adiponectin and decreasing leptin, resistin, and tumor necrosis factor-α (TNF-α) [152]. 
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More specifically, PPAR-γ target genes are effective in adipocyte hormones and 
influencing the release of free fatty acid from adipocytes.  
 Insulin signaling is suppressed by elevation of free fatty acids in the skeletal muscle 
and liver, thus insulin resistance might also be a consequence of free fatty acid 
metabolism. The differentiation of preadipocytes into adipocytes requires PPAR-γ as a 
transcriptional factor. Treatment with TZDs causes a decline in abdominal fat and an 
increase in subcutaneous fat in diabetic patients [151]. The insulin sensitizing property of 
PPAR-γ is believed to be achieved thru the activation of fatty acid transporters (FATP1 
and CD36) and glycerol kinase.  The activation of the above proteins can cause retention 
of fatty acids in the adipose tissue. A clinical study showed that a dominant mutation of 
PPAR-γ resulted in a syndrome of critical hyperinsulinemia and early stage of 
hypertension [153].  
 The functions of the target genes of PPAR-α and PPAR-γ are discussed below. 
Lipoprotein lipase (LPL) promotes clearance of lipid from both chylomicrons and VLDL 
for storage as triacylglycerol in adipose tissue. Acetyl-CoA carboxylase (ACC-α) is an 
isoform of acetyl CoA carboxylase which is the regulatory enzyme in fatty acid synthesis. 
Acyl CoA oxidase (ACOX1) utilized molecular oxygen and produces hydrogen peroxide 
in the first step of lipid oxidation in the liver [154]. Fatty acid transport protein (FATP) is 
a transporter protein located in the plasma membrane that imports free fatty acids into 
hepatocytes [155]. Medium-chain acyl-CoA dehydrogenase (MCAD) is the enzyme 
which initiates breakdown of acyl-CoA into acetyl-CoA during β-oxidation in the 
mitochondria [155]. Hormone sensitive lipoprotein lipase (HSL) hydrolyzes 
triacylglycerol to monoacylglycerol in fatty acid oxidation. The translocation of glucose 
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transport protein 4 (GLUT4) from adipocyte cytosol to the plasma membrane is 
stimulated by insulin and GLUT4 is responsible for the transport of glucose into the 
cytosol. TNF-α is secreted by adipocytes and is increased in obesity, known to contribute 
to insulin resistance [154]. Adipocyte protein 2  (aP2), also called fatty acid binding 
protein, is a known PPAR-γ target gene which is mostly expressed in white adipose tissue 
[156]. Adiponectin is a plasma protein primarily secreted from adipose tissue which is 
responsible for regulating glucose and lipid homeostasis [157].  
 The detail of PPAR-α and PPAR-γ agonists are being discussed in the following 
section.  
  
 
PPARs agonists-fenofibrate and rosiglitazone 
 Fenofibrate 
Fenofibrate, an isopropyl ester of 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl 
propanoic acid, was first identified by Thorp and Waring in 1962 [158]. It has a chemical 
formula of C20H21O4Cl and a molecular weight of 306.83 Da [159]. Fenofibrate is 
insoluble in water but quickly converts to the water soluble and pharmacologically active 
form, fenofibric acid, following oral administration [160].  
Fenofibrate as well as its fibric acid derivatives influence plasma lipoprotein 
levels by regulating the synthesis and clearance of lipoproteins. It can affect many 
pathways involved in lipid metabolism, cholesterol esterification, platelet aggregation, 
and platelet-derived growth factor (PDGF) [161]. The intake of fenofibrate causes several 
side effects in patients. The most common ones are skin problems, gastrointestinal 
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effects, muscle pain, and sweating or dizziness [15]; especially rhabdomyolysis is seen in 
elderly patients [16]. Although an isolated incidence, fenofibrate has been reported to 
increase myopathy [162]. Moreover, combination of fenofibrate with statin has been 
shown to cause rhabdomyolysis [163]. 
 Fenofibrate and its metabolite fenofibric acid are ligands for PPAR-α. Fenofibrate 
reduces plasma triglyceride concentration by up-regulating the expression of genes 
involved in β-oxidation. Other potential benefits of fenofibrate are decreasing platelet 
aggregation and the level of plasma fibrinogen [164]. The mechanism for fenofibrate-
induced reduction in total cholesterol and LDL is not quite clear. In human studies, 
treatment with fenofibrate or its fibric acid derivatives significantly reduced the level of 
LDL, VLDL and total cholesterol due to suppression of cholesterol synthesis [165-168]. 
Fenofibrate had been shown to inhibit the activity of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase, a rate-limiting enzyme involved in cholesterol synthesis and 
clearance [169]. Moreover, fenofibrate have been shown to increase the formation of bile 
from cholesterol, leading to intracellular cholesterol reduction and LDL receptor 
generation in the liver [170].  
 Fibric acid derivatives are also known to raise plasma HDL due to rapid 
generation of the HDL apolipoproteins A-I and A-II. Fenofibrate also promotes the 
clearance of apo AI; however, the increase in generation exceeds clearance, and thus 
there is an overall increase in apo A-II. Activity of lecithin-cholesterol acyltranferase 
(lCAT), an enzyme that functions on the exterior of HDL particle that converts 
intravascular free cholesterol to cholesteryl ester, was shown to be enhanced by 
fenofibrate resulting to an increase in plasma HDL levels [170].    
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 A 15-year clinical trial on fenofibrate was done in 1980s and over 3,500 patients 
participated in the research [171]. Oral administration of fenofibrate for one month 
resulted in a decrease in plasma triglyceride by 30-60%. A similar reduction of 
triglyceride concentrations was observed in a study by Tesone and colleagues [172]. In 
patients with type IIb hyperlipoproteinemia (i.e. elevated LDL and VLDL), fenofibrate 
reduced triglycerides by approximately 30% and total plasma cholesterol by about 20% 
[170]. The recommended dosage of fenofibrate is 300 mg/day. A reduction of LDL 
cholesterol was observed in patients with type IIa hyperlipoproteinemia being treated 
with fenofibrate [173]. In clinical trials, the continuous intake of fenofibrate (300mg/day) 
causes decline in total and LDL cholesterol and elevation in HDL concentration [174]. 
An animal study by Rodney and colleagues [175] showed that fenofibrate 
upregulates lipoprotein lipase resulting to an increase in triglyceride clearance in the liver 
and other tissues. The upregulation of lipoprotein lipase also decreases the production of 
triglyceride in the liver resulting in a decrease of the release of substrate from adipose 
tissue [175]. Fenofibrate was also shown to reduce plasma triglyceride concentration by 
approximately 40% in mice fed fructose diet [176]. Another animal study showed that 
fenofibrate decreased plasma triglyceride levels but increased LDL [177]. 
 
 Rosiglitazone  
Rosiglitazone [(±)-5-[[4-[2-(methyl-2-pyridinylamino)-ethoxylphenyl] methyl]-2, 
4-thiazolidinedione, (Z)-2-butenedioate (1:1)] is a PPAR-γ agonist belonging to the TZD 
family [178].   
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 The mechanism of action of rosiglitazone is not related to sulfonylureas, 
biguanides, or α-glucosidase inhibitors. Rosiglitazone is a PPAR-γ agonist, which acts 
mostly on adipose tissue [7]. Rosiglitazone binds with higher affinity to PPAR-γ 
compared to other TZDs [179]. The ligand dependent activation of PPAR-γ induces gene 
expression involved in adipogenesis, insulin signaling, and glucose transport. Therefore 
activation of PPAR-γ has the effect of reducing insulin resistance in target tissues [180].  
There are several ways by which rosiglitazone contributes to the treatment of 
T2DM. Rosiglitazone enhances insulin sensitization in target tissues without promoting 
the pancreatic secretion of insulin [181]. GLUT4 is a target gene of PPAR-γ and its 
production and translocation take place whenever PPAR-γ is activated, since GLUT4 is 
an insulin-dependent transporter. Under healthy conditions, insulin promotes the 
translocation of GLUT4 to the cell surface to facilitate glucose uptake [179]. If GLUT4 
expression is diminished at the cell surface, glucose uptake is reduced and it is considered 
the primary cause of the development of insulin resistance [182]. PPAR-γ activation may 
also decrease hepatic glucose production and may promote insulin-dependent glucose 
uptake in adipose tissue and skeletal muscle [179]. Rosiglitazone stimulates the 
differentiation of adipocytes and suppresses the release of fatty acids from adipose tissue 
[183]. 
Rosiglitazone decreases the expression of lipoprotein lipase and adipocyte lipid-
binding protein, enzymes involved in fatty acid metabolism in the adipose tissue [184-
185]. Rosiglitazone has also the potential to reduce the expression of leptin in vivo and in 
vitro, an adipokine controlling appetite and energy expenditure [186].  
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 Rosiglitazone can also indirectly promote glucose uptake by the skeletal muscle 
thru improving insulin sensitivity [187]. Activated PPAR-γ stimulates adipocytes to 
signal the skeletal muscle to increase insulin sensitivity. Both in vivo and in vitro 
evidences indicate that TNF-α participates in this signaling pathway since elevation of 
TNF-α induces insulin resistance in adipose tissue [188]. Rosiglitazone suppresses the 
inhibitory effects of TNF-α on insulin activity [183, 189].  
 In humans, rosiglitazone improves insulin sensitivity and secretion, glucose 
tolerance, and adipocytokines in T2DM patients [190]. T2DM patients receiving 
rosiglitazone for three months exhibited significant reductions in HbA1C, fasting plasma 
glucose, fasting free fatty acid, mean glucose GTT, and plasma TNF-α. Also, there was a 
significant increase in insulin sensitivity despite increases in body weight. These results 
demonstrate that rosiglitazone improves insulin sensitivity and secretion, and the 
circulating level of plasma adipokines [190]. Another clinical study showed that T2DM 
patients treated with rosiglitazone exhibited a 9-14% drop in LDL level and a 5-15% 
elevation in HDL concentrations [191].  
 Because of the side effects associated with current pharmacotherapy, nutrition 
therapies are being explored for lowering blood glucose and cholesterol concentrations. 
Natural food products containing bioactive compounds are continuously being 
investigated for their potential in reducing chronic conditions such as obesity and 
diabetes [17-18]. 
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Health benefits of mango 
 For this section, studies on mango were divided according to the part of mango 
used for the study (pulp, peel, kernel, plant) or how it is prepared, such as stem bark 
extraction or seed extraction. 
 
Mango flesh or pulp 
Mango (Mangifera indica L.) is a tropical fruit relatively rich in various nutrients 
and phytochemicals such as polyphenols, vitamin C and dietary fiber. Mango flesh or 
pulp is the only edible part of the fruit.  The mango flesh contains polyphenols, 
terpenoids, carotenoids, fatty acids [23, 192] and other trace elements such as calcium, 
vitamin A and C [193]. Over 180 compounds have been identified in at least 20 cultivars 
of mango. Total concentration of these compounds is about 18-123 mg/kg the fresh fruit 
[194]. The typical composition of mango pulp is reported in Table 1.  
Ribeiro and colleagues [27] investigated the pulp composition in four varieties of 
mango (Haden, Tommy Atkins, Palmer and Uba) and three potential antioxidant 
substances (total phenolics, carotenoids, and ascorbic acid). The variety with each 
phytochemical is listed in Table 2. Clearly there are varietal differences in terms of 
nutrient and antioxidant content of mango [27]. 
 The first study on mango flesh was conducted by Frylinck and Dubery [195]. In 
this experiment, a calcium-dependent protein kinase was purified from the extract of 
ripening mango fruit tissue [195]. This isolated protein phosphorylates histone III-S to a 
lesser extent of casein kinase phosphorylating substrates on serine or threonine residues. 
This particular protein kinase may be an important enzyme in the ripening process of the 
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mango fruit because ripening is known to involve increased turnover of membrane 
inositol phospholipids which, in turn, is often coupled to increases in intracellular 
calcium ion [195]. 
 
Table 1. Typical nutrient composition of mango pulp [196] 
Nutrient  Units Value per 100 grams 
Protein g 0.51 
Total lipid (fat) g 0.27 
Carbohydrate (by difference) g 17.00 
Total dietary fiber g 1.8 
Total sugars g 14.80 
Calcium mg 10 
Potassium mg 156 
Phosphorus mg 11 
Magnesium mg 9 
Vitamin C (total ascorbic acid) mg 27.7 
Total folate mg 14 
Vitamin A IU 765 
β-carotene mcg 445 
Vitamin E mg 1.12 
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Table 2.The pulp compositin in four mango cultivars 
 
Haden Uba Palmer 
Tommy 
Atkins 
Total phenolic 
(mg/100g) 
48.4 208.7   
Total 
carotenoid 
(mg/100g) 
1.91  2.63  
β-carotene 
(µg/100g) 
 2220 661.27  
Total ascorbic 
acid 
(mg/100g) 
 77.71  9.79 
 
The anticancer and antioxidant effects of mango juice and juice extract have also 
been reported [26]. The antioxidant property of mango juice and juice extract was 
assessed using three standard methods: 1, 1-diphenyl-2-picrylhydrazyl (DPPH), oxygen 
radical absorbance capacity (ORAC), and Folin’s assay. The anti-cancer property was 
evaluated by determining the effect on cell cycle and neoplastic transformation of 
mammalian BALB/c 3T3 cells [26]. The results of antioxidant property of mango juice 
and juice extract obtained from three standard methods were consistent with each other. 
Treatment with mango juice and juice extracts showed an inhibitory effect on the G0/G1 
phase of cell cycle progression. In neoplastic transformation assay, whole mango juice 
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significantly reduced amount of transformed foci, indicating the suppressive effect of 
mango juice exerts on tumor cells [26].  
A study by Prasad and coworkers [197] determined the hepatoprotective effects of 
mango using Swiss albino mice given 7-12-dimethylbenzanthracene (DMBA). After 
treatment with lupeol (an effective inhibitor in laboratory models of prostate and skin 
cancers) and mango pulp extract, DMBA-induced oxidative stress was improved, as 
indicated by the restored antioxidant enzyme activities and reduced lipid peroxidation. 
They also found that lupeol and mango pulp extract effectively reduced apoptosis in the 
mouse liver [197].  
A similar study [198] explored the antioxidant effect of lupeol and mango pulp 
extract in response to androgen-induced oxidative stress using Swiss albino mice. 
Animals received oral treatment of either lupeol or mango pulp extract along with 
testosterone injection for 15 days. At the end of the study, prostate samples were 
collected and reactive oxygen species (ROS), lipid peroxidation, and activity of 
antioxidant enzymes were assessed. Supplementations with lupeol and mango pulp 
extract each reduced ROS and lipid peroxidation and restored abundance of antioxidant 
enzymes [198]. The results demonstrated a fact the mango pulp can be used as an 
antioxidant agent.  
 
 
Mango peel 
 Mango peel is one of the inedible parts of mango and a major by-product in pulp 
manufacturing. Some bioactive compounds have been characterized from mango peel 
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including 5-alkyl-and 5-alkenylresorcinols [199]. These bioactive molecules are believed 
to have potential pharmacological effects that relate back to their use as traditional 
medicine [200]. 
 5-(11’ Z-heptadecenyl) - and 5(8’Z, 11’Z-heptadecadienyl)-rescorcinols were also 
purified from mango peel and they can potentially inhibit the activity of cyclooxygenase 
COX-1 and COX-2, known pro-inflammatory mediators [199]. Furthermore, a study 
demonstrated that mango peel inhibited hydrogen peroxide-induced hemolysis in a dose 
dependent manner [193]. The mango peel extract also prevented membrane protein from 
degradation induced by hydrogen peroxide. These findings supported that mango peel 
contains compounds which can protect erythrocytes against oxidative stress [193].    
 
Mango kernel or seed 
 The mango kernel has also been utilized in research [201-202]. Mango kernel 
contains twenty-one gallotannins (15.5mg/g) which may contribute to its antioxidative, 
immunomodulatory, analgesic, and anti-inflammatory properties [203]. In an immune 
response study, the findings showed that mango kernel treatment effectively improved 
superoxide anion production, serum protein, albumin, and survivability in fish treated 
with dried mango kernel compared to the control group [202], and the resutls 
demonstrated that mango kernel enhanced immune response and allowed fish to be more 
resistant to pathogen infection. In addition, methanolic and aqueous extracts of mango 
seed have been shown to have potential anti-diarrheal activity in diabetic mice [201]. 
 
 
 30
Mango stem bark extract 
Several phenolic components have been purified from mango stem bark [204]. 
The major phenolic compounds isolated from the stem bark include mangiferin, gallic 
acid, 3,4-dihydroxy benzoic acid, gallic acid methyl ester, gallic acid propyl ester, (+)-
catechin, (-)-epicatechin, and benzoic acid and benzoic acid propyl ester [204]. Vimang-
® is the brand name of aqueous extract of Mangifera indica family stem bark and 
mangiferin is the major polyphenol present in Vimang [205].  
 
Anti-diabetic and hypolipidemic effect of stem bark extract 
To our knowledge, very few studies have been conducted on glucose lowering 
and hypolipidemic effects of mango. Aderibigbe and colleagues [206] determined the 
glucose lowering effects of mango extract using a streptozotocin (STZ)-induced diabetic 
mice model. Their findings showed that mango aqueous stem bark extract significantly 
reduced blood glucose in STZ-induced diabetic mice compared to the hypoglycemic drug 
chlopropanid. Another study conducted by the same group indicated that aqueous extract 
of mango leaves has also been shown to prevent glucose-induced hyperglycemia in STZ-
induced diabetic rats [206].  
Another in vivo study demonstrated that daily oral treatment with one of the two 
doses of mangiferin (10 and 20 mg/kg) for 28 days had an anti-diabetic effect and 
atherogenic potential in STZ-induced diabetes in rats. Significant reductions in plasma 
glucose concentration due to mangiferin were observed in this animal model. 
Furthermore, mangiferin exhibited a hypolipidemic effect as shown by significant 
reductions in plasma total cholesterol, triglycerides, and LDL concentrations along with 
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an increase of HDL-cholesterol. The findings of this study provide evidence of the anti-
diabetic and hypolipidemic properties of mangiferin [207].  
 In an in vivo study [208], Mangifera indica bark extract exhibited the highest 
percentage inhibition of α-glucosidase compared with Swertia chirata whole plant and 
Lawsonia inermis leave extract. Swertia chirata is in the gentianaceae family and 
commonly seen as clearing nut tree and Lawsonia inermis is a flowering plant named 
Henna that has been traditionally used for body stain. The inhibitory effect of Mangifera 
indica bark extract on α-glucosidase may explain the role of mango in preventing obesity 
and diabetes. 
 
Anti-inflammatory effect of stem bark extract 
 The anti-inflammatory properties of mango extract have also been explored. 
Garrido and colleagues [209] conducted a study on the analgesic and anti-inflammatory 
effects of Vimang-®. Vimang-® at a dose of 50-1000 mg/kg significantly inhibited 
formalin-induced pain (an indicator of analgesic function) and edema (an indicator of 
anti-inflammatory function) in mice. The same group [210] tested the anti-inflammatory 
activity of Vimang both in vivo and in vitro. The in vivo study demonstrated that 
arachidonic acid and phorbol myristate acetate-induced ear edema was reduced after 
application of Vimang [210]. Vimang also reduced serum levels of TNF-α in this animal 
model of inflammation. Vimang inhibited the induction of PGE2 in stimulated 
macrophage cells (RAW 264.7) [210].  
 García and colleagues [211] investigated the effect of Vimang on specific mouse 
antibody generation induced by inoculation of parasites in mice spleen cells. Vimang but 
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not mangiferin, significantly decreased antibody production from the third week after 
inoculation and the inhibitory activity reached a peak at fourth week after inoculation. 
Vimang also significantly suppressed the production of IgG but not IgM, which suggestes 
that the primary antibody against antigens is not affected by Vimang. Mangiferin had no 
effect on neither IgM nor IgG2a, but significantly improved production of IgG1 and 
IgG2b. These results suggested that mango stem bark extracts may play a role in 
modulating the humoral response in mouse spleen cells. 
Vimang and mangiferin have also been shown to suppress the expression of 
COX-2 and nitric oxide synthase in Wistar Kyoto (WKY) and spontaneously 
hypertensive (SHR) rats [212]. Vimang (0.5-0.1 mg/ml) and mangiferin (0.025 mg/ml) 
inhibited nitric oxide synthase expression (smooth muscle) more in SHR than in WKY 
rats whereas COX-2 was expressed more in WKY than in SHR. Their findings 
demonstrate that certain doses of both Vimang and mangiferin suppressed the expression 
of nitric oxide synthase and COX-2 indicating the anti-inflammatory property of Vimang.  
 Ojewole [25] used a powder form of stem bark extract of Mangifera indica to 
examine its potential analgesic, anti-inflammatory, and antidiabetic effects in laboratory 
animals. Mice were used to investigate the analgesic effects while rats were used for 
assessing the anti-inflammatory and anti-diabetic properties. Significant dose-dependent 
analgesic effects were observed in mice given 50-800 mg/kg of stem bark extract 
compared to mice fed morphine (analgesic reference). The same dose of the extract 
significantly inhibited inflammatory-induced paw edema and lowered glucose level in 
rats.  
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 The effect of Vimang on eosinophil migration in an animal model of asthma has 
also been investigated [213]. Eosinophil migration into the bronchoalveolar space was 
decreased by Vimang treatment (50 mg/kg for 18 days) of Toxocara canis-infected 
BALB/c mice. Along with the reduction of eosinophil migration, reduction of IL-5 in 
serum and eotaxin in the lungs was observed and therefore prevented animal from 
inflammation. Moreover, Vimang treatment was determined non-toxic to laboratory 
animals since normal body weights were maintained during infection. The findings of 
this study demonstrated the anti-inflammatory effect of Vimang and its potential use in 
the treatment of eosinophilic disorders, such as eosinophilic esophagitis, eosinophilic 
gastritis and eosinophilic colitis [213]. 
Mangiferin along with other major phenolic compounds, catechin and 
epicatechin, were shown to effectively attenuate human T lymphocytes activation-
induced cell death by downregulating the intracellular levels of reactive oxygen species 
(ROS) and calcium [214]. Activation-induced cell death was required to maintain 
peripheral lymphocyte homeostasis and is induced by ROS with calcium influx into the 
cytosol [214].  
 
Antioxidant effect 
 A compound purified from stem bark extract of Mangifera indica L., QF808, was 
shown to modulate protein and hepatic microsome peroxidation [215]. QF808 reduced 
oxidation and lipid peroxidation in bovine serum albumin (BSA), but the activity of 
NADPH-dependent cytochrome P-450 reductase was not affected. These results 
suggested that QF808 have potent antioxidant activity possibly acting as a free radical 
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scavenger in lipid peroxidation.  
Stem bark extract of Mangifera indica L. also protected T lymphocytes against 
activation-induced cell death in an in vitro study [216]. The stem bark extract attenuated 
the accumulation of reactive oxygen species and intracellular Ca2+, factors required in the 
expression of CD95L which plays a role in AIDS. Furthermore, stem bark extract also 
inhibited activation-induced cell death which is stimulated by T cell receptor and triggers 
an intracellular signaling pathway that promotes the formation of ROS and the increase in 
cystolic Ca2+. Therefore, stem bark extract allows the enhancement of T-cell survival 
[216]. 
Another in vitro study by Rodriguez and colleagues [217] compared the effects of 
mangiferin with epigallocatechin gallate (EGCG) on energy metabolism and 
malondialdehyde formation, an indicator of oxidative stress. The study found that 
treatment with Vimang, mangiferin, and EGCG significantly increased the resistance to 
oxygen species production induced by hydrogen peroxide in human erythrocytes [217]. 
Hydrogen peroxide-initiated energy charge potential was restored with treatments in a 
dose-dependent manner. The treatments also increased the level of energy metabolism 
related compounds that were depleted by hydrogen peroxide damage such as ATP, GTP 
and total nucleotides [217]. 
 The antioxidant effect of Vimang was further investigated using an in vivo study 
[218]. Vimang inhibited degradation of 2-deoxyribose mediated by Fe (III)-EDTA plus 
ascorbate. This result illustrated that Vimang dose not simply remove OH. radicals to 
inhibit 2-deoxyribose degradation, but acts as an anti-oxidant by complexing iron ions 
[218]. Similarly, Andreu [219] demonstrated that Vimang exhibit iron-complexing 
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property and protect the liver mitochondria against lipoperoxidation induced by Fe2+ -
citrate. Vimang (equivalent to 10 µM mangiferin) protected rat liver mitochondria against 
mitochondrial swelling induced by Fe+2-citrate [219]. The stem bark extract also 
functioned as a free radical scavenger to protect the mitochondria from lipoperoxidation, 
confirming the potential antioxidant effect of Vimang [219]. 
 Sánchez and colleagues [220] investigated the effect of Vimang on hepatic 
ischemia/reperfusion-associated injury. Female Wistar rats with hepatic ischemia 
received an oral treatment of Vimang (50, 110, and 250 mg/kg of body weight) for seven 
days. Ischemia/reperfusion-induced transaminase elevation and DNA fragmentation were 
reduced in a dose-dependent manner by Vimang. These findings suggested that Vimang 
could be used as a natural treatment for preventing oxidative damage induced by hepatic 
injury. 
An in vivo study demonstrated the effect of Vimang against oxidative stress 
cytotoxicity in rat hepatocytes [221]. Male rats fed diet containing different 
concentrations of Vimang (20, 50 and 100 µg/ml) had lower glucose-glucose oxidase 
induced ROS formation in hepatocytes. Hepatocyte cytotoxicity and lipid peroxidation 
were both suppressed by Vimang in a dose- and time-dependent manner. In addition, 
Vimang also inhibited superoxide radical formation [221].   
 In isoproterenol-induced myocardial infarcted rats, the enzyme activities involved 
in the tricarboxylic acid cycle and antioxidant defense system were inhibited and lipid 
peroxidation was promoted in the heart mitochodria [222]. In mangiferin-pretreated rats, 
fatty acid oxidation was improved and enzyme activities were restored in isoproterenol-
induced myocardial infarcted rats [222]. The activities of serum lactate dehydrogenase 
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and creatine phosphokinase isoenzymes were elevated in isoproperenol-treated rats, 
indicating myocardial damage. Treatment with mangiferin significantly elevated the 
levels of heart tissue enzymatic antioxidants and serum non-enzymatic antioxidants 
compared to isoproterenol-treated rats.  These results suggest a protective effect of 
mangiferin against isoproterenol-induced myocardial infarction [222]. 
A recent in vivo study demonstrated the ability of Vimang or mangiferin in 
preventing oxidative stress in murine mitochondria of LDL receptor knockout mice 
[223]. The LDL receptor knockout mice were more sensitive to oxidative stress and 
mitochondrial membrane permeability transition, increasing its risk of developing 
atherosclerosis. Oral supplementation with Vimang or mangiferin altered the membrane 
permeability transition to control levels in LDLr-null liver mitochondria. Vimang or 
mangiferin also significantly decreased the production of ROS in both LDLr-null liver 
mitochondria and spleen lymphocytes. Vimang and mangiferin restored both the 
antioxidant capacity and organelle oxidation-reduction homeostasis in the liver 
mitochondria of atherosclerosis-prone mice.  
 Another in vivo study demonstrated the anti-inflammatory and antioxidant effects 
of the stem bark aqueous extract of Mangifera indica [224]. Stem bark extract inhibited 
early and late stage T cell activation, as well as the development the S-phase of cell cycle 
and proliferation induced by T cell receptor [224]. TNF-α-induced IκBα degradation and 
the binding of NF-κB and DNA are also inhibited by stem bark extract [224].   
 The protective effect of Vimang against oxidative stress was also studied in 
elderly humans [225]. Elderly subjects (>65 years) received 900 mg of mango stem bark 
extract daily for 60 days. The plasma lipid peroxides and oxidized glutathione (GSSG), 
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serum peroxidation potential, extracellular superoxide dismutase activity and total 
antioxidants were measured at baseline and 15, 30, and 60 days after treatment. Vimang 
significantly increased the activity of extracellular superoxide dismutase and total 
antioxidants in elderly participants in comparison to young subjects (<26 years). Vimang 
also decreased the level of GSSG in elderly subjects. All the above observations suggest 
that Vimang is effective in preventing age-related oxidative stress in humans [225]. 
 
Anti-allergic effect 
The anti-helmintic and anti-allergic properties of Vimang and mangiferin in 
laboratory mice were investigated by García and colleagues [226]. Vimang (500 mg/body 
weight/day) or mangiferin (50 mg/body weight/day) was given to mice infected with 
Trichinella spiralis throughout the parasite life cycle. Oral treatments of both Vimang 
and mangiferin significantly decreased the number of parasite larvae in the musculature, 
but did not influenced adult parasites in the gut. Results also suggest that treatment with 
Vimang or mangiferin significantly reduced serum level of anti-Trichinella IgE which 
plays an important role in the pathogenesis of allergy. 
The anti-allergic effects of Vimang were also demonstrated in female Balb/c mice 
with inflammatory allergy [227]. At the beginning of the study, mice were immunized by 
intraperitoneal injection of 100 µg of ovoalbumin (OVA). Mice received the same 
amount of OVA a week after first immunization. Twenty-one days after first 
immunization, Vimang at concentration of 50, 100 or 250 mg/kg and 50 mg/kg of 
mangiferin was given to the mice. The primary finding of the study was that both Vimang 
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and mangiferin decreased IgE serum levels in OVA-immunized mice, suggesting an anti-
allergic effect [227]. 
 
Radioprotective effect  
The radioprotective effect of mangiferin was demonstrated using DBAxC57BL 
mice [228]. Mice received different dosages of mangiferin one hour prior to the radiation 
exposure. Results indicated that mangiferin treatment decreased the symptoms of 
radiation sickness and mortality compared to the control group. The radioprotective effect 
of mangiferin increased in a dose-dependent manner and reached peak at a concentration 
of 2 mg/kg body weight. 
 
Cytotoxic effect 
The cytotoxic effects as well as possible interactions of Vimang with P450 
enzymes and how it affects GSH and lipid peroxidation were examined in rat hepatocytes 
[229]. No cytotoxic effects were detected 24 hours after Vimang (up to 1000 µg/ml) 
treatment and a moderate cytotoxicity was monitored 48 hours to 72 hours after exposure 
at concentration of 500 and 1000 µg/ml. Vimang at concentration above 100 µg/ml acts 
as a modulator for P450 enzymes. GSH protein and lipid peroxidation were significantly 
inhibited after a 36 hours pretreatment with Vimang at concentration of 25-200 µg/ml.  
The cytotoxic effect of mangiferin was examined in rat hepatocytes by Rodeiro 
and colleagues [230]. A moderate cytotoxic effect was detected after 72 hours of 
treatment with mangiferin. Moreover, mangiferin decreased the activity of P450 enzymes 
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in a concentration dependent manner after 48 hours exposure, indicating interaction 
mangiferin with metabolism [230].  
 
Other protective effects of stem bark extract 
 Mangiferin also exhibited a gastroprotective effect against gastric injury induced 
by ethanol and indomethacin in rats [231]. The protective effects of mangiferin on gastric 
damage were determined by alterations in mean gastric lesion area. Mangiferin at 
concentrations of 3, 10 and 30 mg/kg body weight decreased ethanol-induced gastric 
damage by 30, 35, and 63%, and indomethacin-induced by 22, 23, and 57%, respectively. 
In addition, mangiferin successfully prevented the depletion of gastric mucosal non-
protein sulfhydryl content in mice, suggesting an antioxidative effect. This study 
provided evidence to support the protection of mangiferin against gastric injury caused by 
ethanol and indomethacin, and a possible underlying mechanism might be mangiferin’s 
antioxidative action.  
In a more recent study, the effect of mango components (i.e. mangiferin and 
quercetin, and a metabolite of mangiferin, norathyriol) on PPARs was examined [232]. It 
is reported that quercetin as well as norathyriol exhibited an inhibitory effect on 
activation on all three subtypes of PPARs. However, mangiferin did not suppress the 
transactivation of any PPARs. This study suggests that components of mango may 
modify the transcription of PPARs and could promote health benefits [232].  
 Vimang or mangiferin also exhibited an effect on preventing iron overload injury 
in rat model [233].  Rats received three dosages of Vimang or 40 mg/kg body weight of 
mangiferin for seven days before and after administration of 100 mg/kg of iron-dextran. 
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Their results demonstrated that Vimang or mangiferin prevented iron overload in plasma 
as well as oxidative stress in hepatocytes and reduce the percentage of saturation and iron 
content in the liver. Moreover, Vimang or mangiferin enhanced serum iron-binding 
capacity and decreased the number of abnormal Kupffer cells in iron-loaded hepatic 
tissue. The authors suggested that Vimang or mangiferin are potential antioxidants and 
promote liver iron excretion to protect liver against iron overload [233].  
 The effect of mango stem bark extract on the contraction of the smooth muscle of 
the trachea of rats was investigated by Agbonon and colleagues [234]. After inducing a 
substantial contraction in the smooth muscle of the trachea of male Wistar rats by 
acetylcholine, the trachea was treated with mango stem bark extract  (1, 2 and 4 mg/ml) 
[234]. Stem bark extract of mango dose-dependently relaxed the isolated trachea in this 
model, indicating possible use of mango in the treatment of asthma. 
 By now, there are many studies conducted on the nutritional benefits of mango 
stem bark extract. However, there is very limited source focusing on the mango flesh 
which is the only edible part of mango. Therefore, we conducted this study to illustrate 
the nutritional benefits of consuming mango flesh in maintaining individual’s health.  
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CHAPTER III 
 
 
METHODOLOGY 
 
Animal care and dietary treatments 
 Fifty two, three-month old C57BL/6J male mice were purchased from Harlan 
Teklad (Indianapolis, IN). Animal handling and procedures were approved by 
Institutional Animal Care and Use Committee at Oklahoma State University. Mice were 
acclimated for three days and were fed with standardized powdered rodent diet (AIN 
93M) [235]. After acclimation, mice were weighed and randomly divided into six dietary 
treatment groups (n=8 mice/ group): (1) AIN-93M [235]; (2) high fat diet (based on 
formulation of [236]); (3) high fat diet with fenofibrate (0.05mg/kg diet, Cayman 
Chemicals, Ann Arbor, Michigan); (4) high fat diet with rosiglitazone (0.005mg/kg diet, 
Cayman Chemicals, Ann Arbor, MI); (5) high fat diet with 1% (w/w) freeze dried mango 
(low dose); and (6) high fat diet with 10% (w/w) freeze dried mango (high dose).  
Tommy Atkins variety mango was freeze dried, ground, analyzed for its nutrient 
composition (Table 3) and incorporated into the diet at 1% or 10% concentration by 
weight. All high fat diets were adjusted to have the same macronutrient composition, as 
well as calcium and phosphorus (Table 4). Mice were given food and deionized water ad 
libitum and were weighed weekly.  
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Glucose tolerance test 
After eight weeks of dietary treatment, a glucose tolerance test was performed 
(n=6 mice/ group). Mice were fasted overnight and 50 µl of blood from the tail was used 
to determine baseline blood glucose concentrations using a home glucose testing kit 
(Onetouch Ultra, LifeScan, Inc. Milpitas, CA). Mice were then injected intraperitoneally 
with 20% glucose solution (2 g/kg body weight). Blood glucose concentration was again 
determined at 5, 15, 30, 60 and 120 minutes post glucose injection. Area under the curve 
was calculated by the trapezoidal rule [237]. 
 
 Necropsy and tissue processing  
After two months of dietary treatment, mice were weighed and injected with 
ketamine/xylazine cocktail (80 and 8 mg/kg body weight, respectively). Body 
composition was determined using a GE Lunar Piximus (Fitchburg, WI). Blood was 
collected from carotid artery into EDTA coated tubes. Plasma was obtained by 
centrifugation of whole blood for 20 minutes at 1306 g and stored at -80°C until further 
analyses. White adipose tissue, liver, spleen, kidney and skeletal muscle were collected. 
White adipose tissue, liver and kidney were weighed, snap-frozen and stored at -80°C. 
Skeletal muscle was snap-frozen and stored at -80°C. 
 
Clinical analyses 
Alfa Wassermann (West Caldwell, NJ) clinical chemistry analyzer was used to 
determine plasma concentrations of glucose, non-esterified fatty acids (NEFA), total 
cholesterol, HDL-C, and triglycerides. Kits were purchased from Alfa Wasserman (West 
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Caldwell, NJ) except for NEFA (Wako Diagnostics, Richmond, VA) and the 
manufacturer’s instructions were strictly followed.  
Plasma glucose concentrations were determined based on its reaction with 
adenosine triphosphate (ATP) in the presence of hexokinase and magnesium which 
produces glucose-6 phosphate and adenosine diphosphate (ADP). Glucose-6-phosphate 
dehydrogenase oxidizes glucose-6-phosphate and NAD+ to form 6-phosphogluconate and 
NADH. The NADH produced, which strongly absorbed at 340nm, is proportional to the 
amount of glucose in the plasma (Alfa Wasserman, West Caldwell, NJ).  
To determine total cholesterol, esterified cholesterol was first hydrolyzed by 
cholesterol esterase to free cholesterol and free fatty acids. Endogenous free cholesterol 
and cholesterol released from cholesterol esters are oxidized by cholesterol oxidase to 
produce hydrogen peroxide (H2O2). Peroxidase then catalyzes the reaction between H2O2, 
p-hydroxybenzoic acid and 4-aminoantipyrine to produce a red-color quinoneimine 
complex which strongly absorbs at 505 nm. The amount of chromogen generated is 
proportional to the total cholesterol concentration when measuring the absorbance at 505 
nm/647 nm (Alfa Wasserman, West Caldwell, NJ). 
The HDL-cholesterol assay uses a unique reagent which solubilizes only the HDL 
lipoproteins and also inhibits reaction of the cholesterol enzymes with LDL, VLDL and 
chylomicron lipoproteins. HDL cholesterol is then released from lipoproteins and reacts 
with cholesterol esterase and oxidase which in the presence of a chromogen produces 
color for detection. Chromogen formation is determined by measuring the absorbance 
bichromatically at 592/692 nm which is proportional to the HDL cholesterol 
concentration (Alfa Wasserman, West Caldwell, NJ). 
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Plasma triglycerides are hydrolyzed by lipase to release glycerol and free fatty 
acids. In the presence of ATP and glycerol kinase, glycerol is phosphorylated to glycerol-
1-phosphate and ATP is converted to ADP. Glycerol-1-phoaphate is then oxidized by 
glycerol phosphate oxidase to produce H2O2. H2O2 reacts with p-chlorophenol and 4-
aminoantipyrine to produce a red-color quinoneimine, a reaction is catalyzed by 
peroxidase. Chromogen formation is determined by measuring the absorbance 
bichromatically at 505/692 nm which is proportional to the triglyceride concentration 
(Alfa Wasserman, West Caldwell, NJ). 
In the presence of ATP and CoA, NEFA is converted to thiol esters of CoA, when 
treated with acyl-CoA synthetase. Then acyl-CoA is oxidized to produce H2O2 in the 
presence of acyl-CoA oxidase and peroxidase. This conversion allows the condensation 
of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 4-aminoantipyrine to create a 
purple-color product which absorbs strongly at 550 nm (Wako Diagnostics, Richmond, 
VA).  
 
Plasma leptin, adiponectin and insulin  
Enzyme linked immunosorbent assay (ELISA) kits from Linco Research (St. 
Charles, MO) were used to determine plasma concentrations of leptin, adiponectin and 
insulin. The wells of microtiter plates were coated with anti-mouse adiponectin, leptin or 
insulin monoclonal antibodies before use. The plate was then coated with a second 
biotinylated anti-mouse polyclonal antibody to capture the analytes in the samples. 
Unbound materials from samples were then washed off and horseradish peroxidase was 
applied on to the immobilized biotinylated antibodies. The activity of horseradish 
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peroxidase was monitored using 3, 3’, 5, 5’-tetramethylbenzidine as a substrate and 
absorbance at 450 nm was measured using a microplate reader (Biotek Synergy, 
Winooski, VT). The captured mouse adiponectin, leptin or insulin in the plasma was 
directly proportional to the increase in absorbance at 450nm/590nm (Linco Research, St. 
Charles, MO).  
 
RNA isolation  
RNA was extracted from the liver, white adipose tissue, and skeletal muscle using 
STAT60 (TEL-TEST INC, TX), chloroform (Sigma, St Louis, MO) and isopropyl 
alcohol (Sigma, St Louis, MO). All the tissue samples were homogenized in STAT-60 
(1ml of STAT-60/50-100 mg tissue). The tubes were left at room temperature for 5 
minutes followed by addition of chloroform (0.2ml chloroform /ml STAT-60). Tubes 
were centrifuged at 11,750 g for 15 minutes at 4°C and the top aqueous layer was 
transferred to a new tube. Isopropyl alcohol (0.5ml/ml STAT-60) was added to each tube 
and was inverted thoroughly. Tubes were left for 10 minutes at room temperature and 
then centrifuged at 11,750 g for 10 minutes at 4°C. The supernatant was discarded and 
75% ethanol (1ml ethanol/1 ml STAT-60) was added to each tube, vortexed, and 
centrifuged again at 4592 g for 5 minutes at 4°C. The supernatant was discarded and the 
precipitated RNA was air-dried for 2-3 minutes and then dissolved in 100 µl DEPC H2O. 
The concentrations and quality of the RNA samples were determined by NanoDrop 
Spectrophotometer (Thermo Scientific, Wilmington, DE). The quality of RNA was 
confirmed with agarose gel electrophoresis. RNA samples were stored at -80 °C until 
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used for RT-PCR. All qRT PCR results were evaluated by the comparative cycle number 
at threshold (CT) method using cyclo or 36b4 as the invariant control.  
 
 
Gene expression by real time-PCR 
 Genes involved in lipid metabolism, PPAR-α, LPL, ACC-α, ACOX1, FATP and 
MCAD were assessed in the liver. Cyclophilin was used as housekeeping gene.  
 For white adipose tissue, genes involved in glucose and lipid metabolism were 
assessed. These genes include HSL, GLUT4, and ACOX1, ACC-α, LPL, and PPAR-γ, 
aP2, and adiponectin.  Cyclophilin was used as housekeeping gene. 
For skeletal muscle, genes involved in both glucose and lipid metabolism 
(GLUT4, ACOX1, ACCα, FATP and MCAD) were assessed and used 36b4 as 
housekeeping gene. The functions of these genes were discussed in the previous section.  
 Amplifications were performed in a 10 µL reaction mix containing unkown 
cDNA samples on a 384-well plate, forward and reverse primers, and SYBR Green I 
PCR reagents (Applied Biosystems, Foster City, CA, USA). The primers used for PCR 
are shown in Table 5. Amplifications of cDNA were detected constantly by realtime 
quantitative PCR on 7900 HT Fast Real-time PCR system (Applied Biosystems, Foster 
City, CA). The  PCR amplification protocol is as follows: (i) initial attenuation at 95°C 
for 10 minutes; and (ii) three-segment amplification and quantification involving 40 
cycles of 50°C for 120 s, 95°C for 10 min, 95°C for 9 s,  60°C for 60 s, 95°C for 9 s, and  
60°C for 9 s.  
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Statistical analyses 
 Statistical analyses involved computation of least square means and standard error 
(SE) for each of the treatment groups using SAS version 9.1 (SAS Institute, Cary, NC). 
Analysis of variance and least square means were calculated using the general linear 
model procedure and the means were compared using Fisher’s least significant difference 
for comparing groups. Differences were considered significant at P < 0.05. 
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Table 3: Nutrient composition of freeze-dried Tommy mango used in the study1 
 
          
Nutrients Amount (g/100 g)  
Protein 3.94  
Fat 6.46 
Fiber 3.84 
Ash 2.19  
Calcium 0.0424  
Phosphorus 0.0941 
Carbohydrate 74.8 
Calories (kcal/100g) 373  
1Nutrient composition was analyzed by NP Analytical Laboratories (St. Louis, MO). 
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Table 4: Composition of the experimental diets 
 
Ingredient Normal 
dieta 
(AIN-93M)  
High fat 
dietb,c 
High fat 
diet + 1% 
mango  
High fat 
diet + 10% 
mango 
amount (g/kg diet) 
Mango  0 0 10 100 
Total carbohydrate 721 370 370 370 
   Cornstarch 621 100 94 25.2 
   Sucrose 100 270 270 270 
   Contribution of mango   7.5 74.8 
Total fat 40 350 350 350 
   Soybean Oil 40 40 39.4 33.5 
   Lard 0 310 310 310 
   Contribution of mango   0.646 6.47 
Total Protein 140 180 180 180 
   Casein 140 180 179.6 176.1 
   Contribution of mango   0.394 3.9 
Total fiber 50 50 50 50 
   Cellulose 50 50 49.6 31 
   Contribution of mango   0.384 3.83 
Vitamin Mix (AIN 93VX) 10 10 10 10 
Mineral Mix (AIN 93 MX) 35 35 35 35 
Choline Bitartrate 2.5 2.5 2.5 2.5 
L-cysteine 1.8 1.8 1.8 1.8 
Tert-butylhydroquinone 0.008 0.008 0.008 0.008 
Kcal/ 100g diete 379 549 553 546 
aBased on AIN-93M formulations containing 72% carbohydrate, 4% fat and 14% protein by 
calories (Reeves et al., 1997). 
bHigh fat diet (37 % carbohydrate, 35% fat and 18% protein by calories) based on formulation of 
Molnar et al (2005).  
cRosiglitazone and fenofibrate were from Cayman Chemicals (Ann Arbor, MI) and added to the 
high fat diet at a dose of 50 and 500 mg/kg diet, respectively. 
eAnalyzed by NP Analytical Laboratories (St. Louis, MO) 
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Table 5: Primers used for real-time PCR 
 
Gene Forward sequence (F) 
Reverse sequence (R) 
Peroxisome proliferator-activated 
receptor alpha (PPARα) 
(F) 5`-CGTACGGCAATGGCTTTATC 
(R) 5`-AACGGCTTCCTCAGGTTCTT 
Peroxisome proliferator-activated 
receptor gamma (PPARγ) 
(F) 5`-CCCACCAACTTCGGAATCA 
(R) 5`-TGCGAGTGGTCTTCCATCAC 
Lipoprotein lipase (LPL) (F) 5`-GGACTGAGAATGGCAAGCAA 
(R) 5`-CCACTGTGCCGTACAGAGAAA 
Hormone sensitive lipoprotein lipase 
(hsLPL) 
(F) 5'-GGAGCACTACAAACGCAACGA 
(R) 5'-TCGGCCACCGGTAAAGAG 
Acyl-Coenzyme A oxidase 1  
(ACOX-1) 
(F) 5'-AGATTGGTAGAAATTGCTGCAAAA 
(R) 5'-ACGCCACTTCCTTGCTCTTC 
Acetyl-CoA carboxylase alpha (ACCα) (F) 5'-GGCAGCTCTGGAGGTGTATG 
(R) 5'-TCCTTAAGCTGGCGGTGTT 
Glucose transporter 4 (GLUT 4) (F) 5`-CCTTTCTCATTGGCATCATTTC 
(R) 5`-CACGGCCAAGACATTGTTG 
Adiponectin (F) 5`-TCACGGTGTACATGAAAGATGTG 
(R) 5`-GAGAACGGCCTTGTCCTTCT 
Tumor necrosis factor alpha (TNFα) (F) 5`-CTGAGGTCAATCTGCCCAAGTAC 
(R) 5`-CTTCACAGAGCAATGACTCCAAAG 
Fatty acid transporter protein 1 
(FATP1) 
(F) 5'-CCGTATCCTCACGCATGTGT 
(R) 5'-CTCCATCGTGTCCTCATTGAC 
Fatty acid transporter protein 5 
(FATP5) 
(F) 5'-GACCACTGGACTCCCAAAGC 
(R) 5'-GACAGCACGTTGCTCACTTGT 
Medium-chain acyl dehydrogenase 
(MCAD) 
(F) 5'-GATGCCATCACCCTCGTGTAAC 
(R) 5'-AAGCCCTTTTCCCCTGAAG 
adipocyte protein 2 (aP2) (F) 5`-GCCAAGCCCAACATGATCA 
(R) 5`-TTCCACGCCCAGTTTGAAG 
36B4 (F) 5'-CACTGGTCTAGGACCCGAGAAG 
(R) 5'-GGTGCCTCTGAAGATTTTCG 
Cyclophilin (cyclo) (F) 5`-TGGAGAGCACCAAGACAGACA 
(R) 5`-TGCCGGAGTCGACAATGAT 
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CHAPTER IV 
 
 
FINDINGS 
 
Food intake, body and tissue weights  
Two mango groups had similar daily food intake compare to fenofibrate, 
rosiglitazone and high fat diet groups. As mice were fed ad libitum, the average food 
intake of the mice receiving the normal diet was significantly greater than those receiving 
the high fat (Table 6). Because of the higher food intake, caloric intake of the mice fed 
normal diet was significantly higher than all the other treatment groups (Table 6).  
After eight weeks of feeding, there were no significant differences in the initial 
and final body weights (Table 6) as well as weekly body weights among groups (Table 
7). Despite similar body weight, adipose tissue weight was highest in the group fed high 
fat diet (Table 6). The two doses of mango, similar to fenofibrate and rosiglitazone, 
prevent the increase of adipose tissue to that of the normal diet (Table 6). Consumption 
of fenofibrate resulted to a significantly heavier liver, an effect not seen in the low dose 
mango (Table 6). There were no significant differences in kidney and spleen weights 
(Table 6). 
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Whole body composition  
There was no significant difference in lean mass among all groups (Table 8). The 
two doses of mango, similar to rosiglitazone and fenofibrate, significantly reduced fat 
mass (Table 8) and percent body fat to the level of those receiving normal diet (Figure 
2). As expected, high fat group had the highest fat mass (Table 8) and percent body fat 
(Figure 2).  
 
Glucose tolerance test  
Mice fed with the normal diet tended (P=0.0544) to have the highest baseline 
glucose concentration while those in the rosiglitazone group the lowest (Table 9). No 
significant differences in blood glucose concentration were observed after 5 and 15 
minutes of glucose injection. However, significant differences were observed after 30, 
60, and 120 minutes after glucose injection (Table 9). Mango supplementation at 1% 
dose is the most effective in normalizing blood glucose concentrations after a glucose 
tolerance test as indicated by comparing the area under the curve (Figure 3). High fat diet 
had the highest blood glucose concentration at these time points while 1% mango had the 
lowest (Table 9). Rosiglitazone, a known hypoglycemic agent, fenofibrate and 10% 
mango is similar to the high fat diet in terms of its effect on area under the curve (Figure 
3).  
 
Clinical chemistry parameters  
There were significant differences in plasma glucose concentration after two 
months of dietary treatment (Figure 4). Mice fed with 1% mango had similar plasma 
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concentration to rosiglitazone group, which was significantly lower than the normal diet, 
high fat diet, and fenofibrate (Figure 4). Mango supplementation at 10% dose had an 
intermediate effect on plasma glucose concentration (Figure 4). 
There were significant differences in plasma total cholesterol among the groups 
after two months of dietary treatment (Figure 5). Mice receiving the normal diet and 
rosiglitazone had the lowest plasma total cholesterol concentrations (Figure 5). 
Interestingly, mice receiving fenofibrate had the highest total cholesterol and those 
receiving high fat diet had an intermediate total cholesterol values (Figure 5). Plasma 
total cholesterol concentrations of mice in the low or high dose mango was similar to the 
rosiglitazone and the normal diet group (Figure 5). 
There were also significant differences in plasma HDL-C concentrations among 
the treatment groups (Table 10). Mice receiving rosiglitazone or the two doses of mango 
had similar HDL-C to those in the normal diet (Table 10). Mice receiving fenofibrate had 
the highest HDL-C (Table 10).  
All other treatment groups reduced NEFA to the level of the normal diet group 
except for the high dose mango which had an in-between effect (Figure 6). Non-
esterified fatty acid (NEFA) was highest in the high fat group (Figure 6).  
There was no significant difference in plasma triglycerides concentrations among 
any of the treatment groups (Table 10).  
 
Plasma leptin, adiponectin and insulin  
 Significant differences in plasma leptin concentrations were observed after two 
months of dietary treatment (Figure 7). Mice in the normal and high fat diet had similar 
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plasma leptin concentrations which was significantly higher than the mice receiving 
mango (Figure 7). Rosiglitazone and fenofibrate had an intermediate effect on plasma 
leptin concentrations (Figure 7).   
 Mice in the high fat diet, fenofibrate and 1% mango had similar plasma 
adiponectin concentrations which was significantly higher than the mice in the 
rosiglitazone group (Figure 8). Mice receiving the high dose of mango had similar 
plasma of adiponectin concentrations to the mice in normal diet and rosiglitazone group 
(Figure 8). 
 There was no significant difference in plasma insulin concentrations among the 
treatment groups (Table 10).   
 
Gene expression by real time PCR 
There were significant differences in the liver gene expression (relative mRNA) 
of enzymes involved in fatty acid synthesis, ACCα and β oxidation ACOX1 and MCAD 
after two months of dietary treatment (Figures 9-14). Low dose mango has similar 
relative ACCα mRNA to that of normal and high fat diet (Figure 9). Relative to the 
normal diet, fenofibrate supplementation had significantly higher gene expression of 
ACCα (Figure 9). High dose mango had the lowest gene expression of ACCα followed 
by rosiglitazone (Figure 9). Similar pattern was observed in the gene expression of 
ACOX1 (Figure 10) and MCAD (Figure 11) in the liver.  
After two months of dietary treatment, there was a significant difference in the 
liver gene expression of the transport protein FATP5 (Figure 12).  High fat and 
fenofibrate groups had significantly higher liver FATP5 gene expression compared to the 
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rosiglitazone and mango groups (Figure 12). Gene expression of transport protein 
FATP1 in the skeletal muscle was not affected by dietary treatment (Table 10). 
Only fenofibrate increased gene expression of liver LPL relative to the normal 
diet group (Figure 13). Normal diet, high fat diet, and fenofibrate treatment had 
significantly higher liver relative mRNA of PPARα than the low and high dose mango 
groups (Figure 14).  
There were no significant differences in the relative mRNA level of genes 
examined in the white adipose tissue (ACCα, ACOX1, adiponectin, aP2, GLUT4, hsLPL, 
LPL and PPAR-γ) and in the skeletal muscle (ACOX1, FATP1, GLUT4, LPL, and 
MCAD) (Table 11).  
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Table 6: Effects of mango, rosiglitazone, and fenofibrate on food intake and body and 
tissue weights of mice fed high fat diet for two months1 
Para-
meters 
AIN-93M High Fat High Fat 
+ 1% 
Mango 
High Fat 
+ 10% 
Mango 
High Fat 
+ Feno-
fibrate 
High Fat 
+ Rosi-
glitazone 
P value 
Food 
intake  
(g/d) 
4.9 ± 0.1a 2.4± 0.1b 2.4 ± 0.1b 2.6 ± 0.1b 2.4 ± 0.1b 2.6 ± 0.1b <0.0001 
Calories 
(kcal/d) 
18.5 ± 
0.3a 13.3 ± 0.3
bc
 
13.5 ± 
0.3bc 14.0 ± 0.3
b
 
13.0 ± 
0.3c 14.2 ± 0.3
b
 
<0.0001 
Body weights (g)  
Initial 23.4 ± 0.5 23.3 ± 0.5 23.3 ± 0.6 23.8 ± 0.6 23.0 ± 0.5 23.1 ± 0.6 0.9342 
Final 29.4 ± 1.0 30.9 ± 1.0 27.7 ± 1.2 29.1 ± 1.1 28.0 ± 1.0 26.8 ± 1.1 0.1136 
Tissue weights (mg)  
Adipose 
tissue 830 ± 164
b
 
1530 ± 
164a 730 ± 186
b
 870 ±174b 828 
±164b 524 ± 174
b
 
0.0037 
Liver 994 ± 46bc 909 ± 46c 897 ± 52c 1058 ± 49b 1644 ± 46a 923 ± 49
bc
 
<0.0001 
Spleen 70 ± 14 63 ± 14 84 ± 16 100 ± 15 66 ± 14 99 ± 15 0.2848 
Kidney 361 ± 11 330 ± 11 343 ± 12 358 ± 12 338 ± 11 341 ± 12 0.3343 
1Values are mean ± SE, n=8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other.  
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Table 7: Effects of mango, rosiglitazone, and fenofibrate on weekly body weights of 
mice fed high fat diet for two months1 
 
 AIN-93M High fat High 
fat+1% 
mango 
High 
fat+10% 
mango 
High fat+ 
Feno-
fibrate 
High fat+ 
Rosigli-
tazone 
P value 
(grams) 
Initial 
weight 23.4 ± 0.5 23.3 ± 0.5 23.3 ± 0.6 23.8 ± 0.6 23.0 ± 0.5 23.1 ± 0.6 0.9342 
Week 1 23.5 ± 0.6 24.7 ± 0.6 24.6 ± 0.7 24.4 ± 0.7 23.8 ± 0.6 23.4 ± 0.7 0.5920 
Week 2 
 
23.4 ± 0.7 24.6 ± 0.7 25.7 ± 0.8 25.3 ± 0.8 24.7 ± 0.7 23.4 ± 0.8 0.2173 
Week 3 
 
26.8 ± 0.8 26.1 ± 0.8 27.3 ± 1.0 27.5 ± 0.9 26.1 ± 0.8 25.3 ± 0.9 0.5114 
Week 4 
 
27.8 ± 0.9 28.3 ± 0.9 29.0 ± 1.0 29.4 ± 0.9 27.1 ± 0.9 26.9 ± 0.9 0.3496 
Week 5 
 
28.5 ± 1.1 29.8 ± 1.1 29.7 ± 1.2 29.4 ± 1.1 27.8 ± 1.1 28.1 ± 1.1 0.6814 
Week 6 
 
29.9 ± 1.2 32.4 ± 1.2 31.0 ± 1.3 31.0 ± 1.2 28.9 ± 1.2 29.3 ± 1.2 0.3175 
Week 7 31.4 ± 1.2 33.1 ± 1.2 31.2 ± 1.4 31.7 ± 1.3 29.6 ± 1.2 29.3 ± 1.3 0.2993 
Final 
weight 29.4 ± 1.0 30.9 ± 1.0 27.7 ± 1.2 29.1 ± 1.1 28.0 ± 1.0 26.8 ± 1.1 0.1136 
1Values are mean ± SE, n=8/group.  
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Table 8: Effects of mango, rosiglitazone, and fenofibrate on lean and fat mass of mice 
fed high fat diet for two months1 
Paramete
rs 
AIN-93M High Fat 
 
High Fat 
+ 1% 
Mango 
High Fat 
+ 10% 
Mango 
High Fat 
+ Feno-
fibrate 
High Fat 
+ Rosi-
glitazone 
P value 
Lean mass 
(g) 20.8 ± 0.5 19.6 ± 0.5 21.1 ± 0.5 20.4 ± 0.5 20.2 ± 0.5 20.5 ± 0.5 0.4847 
Fat mass 
(g) 7.2 ± 1.0b 10.1 ± 1.0a 5.4 ± 1.0b 6.8 ± 1.0b 6.5 ± 1.0b 5.7 ± 1.0b 0.0255 
1Values are mean ± SE, n=8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other. 
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Table 9: Effects of mango, rosiglitazone, and fenofibrate on blood glucose during a 
glucose tolerance test of mice fed high fat diet for two months1 
 
 AIN-93M High fat High fat +1% 
mango 
High fat 
+10% 
mango 
High fat 
+Feno-
fibrate 
High fat + 
Rosigli-tazone 
P value 
(mg/dl) 
Baseline 
153.7±11.1 120.7 ± 11.1 112.3 ± 12.0 127.3 ± 12.0 128.1 ± 11.1 102.1 ± 11.1 0.0544 
5 min 262.0 ± 21.4 234.0 ± 21.4 259.3 ± 23.2 233.8 ± 23.2 247.7 ± 21.4 178.3 ± 21.4 0.1025 
15 min 431.4 ± 29.0 407.3 ± 29.0 382.0 ± 31.3 352.2 ± 31.3 417.0 ± 29.0 377.4 ± 29.0 0.4623 
30 min 389.6 ± 30.7bc 490.0 ± 30.7a 349.8 ± 33.2c 420.8 ± 33.2abc 467.3 ± 30.7ab 
431.7 ± 
30.7abc 0.0441 
60 min 319.9 ± 34.5ab 413.3 ± 34.5a 216.8 ± 37.3b 351.5 ± 37.3a 373.6 ± 34.5a 323.9 ± 34.5a 0.0137 
120 min 171.0 ± 21.9ab 217.3 ± 21.9a 114.7 ± 23.7b 232.7 ± 23.7a 167.6 ± 21.9ab 188.3 ± 21.9
a
 0.0177 
1Values are mean ± SE, n=6/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other.  
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Table 10: Effects of mango, rosiglitazone and fenofibrate on plasma triglycerides, HDL-
cholesterol, and insulin concentrations of mice fed high fat diet for two months1  
 
Para-
meters 
AIN-93M High Fat High Fat + 
1% Mango 
High Fat + 
10% 
Mango 
High Fat + 
Feno-
fibrate 
High Fat + 
Rosi-
glitazone 
P value 
TG 
(mg/dl) 53.2 ± 6.8 52.1 ± 6.8 58.4 ± 7.7 38.4 ± 7.7 36.1 ± 6.8 46.5 ± 7.2 0.2146 
HDL 
 (mg/dl) 37.0 ± 4.1c 52.9 ± 3.9b 41.2 ± 4.8bc 44.1 ± 4.4bc 75.6 ± 3.9a 33.7 ± 4.4c <0.0001 
Insulin 
(ng/ml) 0.19 ± 0.02 0.23 ± 0.02 0.20 ± 0.02 0.19 ± 0.02 0.19 ± 0.02 0.18 ± 0.02 0.2674 
1Values are mean ± SE, n=8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other. TG=triglycerides, HDL=high density lipoprotein 
cholesterol. 
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Table 11: Effects of mango, rosiglitazone, and fenofibrate on gene expression (relative 
mRNA) in white adipose tissue and skeletal muscle of mice fed high fat diet for two 
months1 
 
1Values are mean ± SE, n=6/group. 
 
 
Para-meters AIN-93M High Fat High Fat + 
1% Mango 
High Fat + 
10% 
Mango 
High Fat + 
Feno-
fibrate 
High Fat + 
Rosi-
glitazone 
P value 
White adipose tissue (Control gene=Cyclo) 
ACCα 
Mean CT =21.0 
1.00 ± 5.2 1.16 ± 5.2 0.99 ± 4.8 11.92 ± 4.8 2.19 ± 4.8 1.35 ± 4.8 0.5431 
ACOX1 
Mean CT =21.0 
1.00 ± 0.5 0.49 ± 0.5 1.19 ± 0.5 1.07 ± 0.5 2.04 ± 0.5 0.93 ± 0.5 0.4379 
Adipo- 
Nectin 
Mean CT =20.4 
1.00 ± 0.3 0.50 ± 0.23 0.80 ± 0.3 0.92 ± 0.3 0.71 ± 0.3 1.31 ± 0.3 0.4306 
aP2  
Mean CT =20.4 
1.00 ± 0.3 0.58 ± 0.3 0.82 ± 0.3 1.04 ± 0.3 0.64 ± 0.3 1.80 ± 0.3 0.0598 
GUT4 
Mean CT =20.7 
1.00 ± 0.3 0.59 ± 0.3 0.73 ± 0.3 0.50 ± 0.3 0.83 ± 0.3 1.00 ± 0.3 0.6595 
hsLPL 
Mean CT =21.0 
1.00 ± 3.4 0.87 ± 3.4 1.42 ± 3.1 7.82 ± 3.1 2.25 ± 3.1 2.68± 3.1 0.6334 
LPL 
Mean CT =20.7 
1.00 ± 0.3 0.59 ± 0.3 125 ± 0.3 0.61 ± 0. 3 1.01 ± 0.3 1.37 ± 0.3 0.3315 
PPARγ 
Mean CT =20.7 
1.00 ± 0.3 0.55 ± 0.3 1.15 ± 0.3 0.59 ± 0.3 0.78 ± 0.3 0.83 ± 0.3 0.6666 
Skeletal muscle (Control gene=36b4) 
ACOX1 
Mean CT =23.2 
1.00 ± 0.1 1.02 ± 0.1 0.9 ± 0.2 1.17± 0.2 0.78 ± 0.1 1.15 ± 0.1 0.4660 
FATP1 
Mean CT =23.7 
1.00 ± 0.9 2.70 ± 0.8 1.25 ± 0.9 2.33 ± 0.9 1.22 ± 0.8 2.08 ± 0.8 0.6317 
GLUT4 
Mean CT =20.6 1.00 ± 0.1 0.81 ± 0.1 0.98 ± 0.1 0.63 ± 0.1 0.62 ± 0.1 0.63 ± 0.2 0.1516 
LPL 
Mean CT =23.2 
1.00 ± 0.1 0.88 ± 0.1 0.83 ± 0.2 0.96 ± 0.2 0.73 ± 0.1 0.79 ± 0.1 0.8073 
MCAD 
Mean CT =23.2 
1.00 ± 0.1 1.32 ± 0.1 1.04 ± 0.1 1.00 ± 0.1 0.93 ± 0.1 0.88 ± 0.1 0.2229 
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Figure 2: Effects of mango, rosiglitazone, and fenofibrate on % body fat of mice fed 
high fat (HF) diet for two months1 
 
 
 
 
1Bars are mean ± SE, n=8/group; bars that do not share the same letters are significantly (P<0.05) 
different from each other. 
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Figure 3: Effects of mango, rosiglitazone, and fenofibrate on glucose area under the 
curve after a glucose tolerance test of mice fed high fat (HF) diet for two months1  
 
 
 
 
1Bars are mean ± SE, n=6/group; bars that do not share the same letters are significantly (P<0.05) 
different from each other. 
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Figure 4: Effects of mango, rosiglitazone and fenofibrate on plasma glucose level of 
mice fed high fat (HF) diet for two months1 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 5: Effects of mango, rosiglitazone, and fenofibrate on plasma total cholesterol 
(TC) concentrations of mice fed high fat (HF) diet for two months1 
 
 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 6: Effects of mango, rosiglitazone, and fenofibrate on plasma non-esterified fatty 
acid (NEFA) concentrations of mice fed high fat (HF) diet for two months1 
 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 7: Effects of mango, rosiglitazone, and fenofibrate on plasma leptin 
concentrations of mice fed high fat (HF) diet for two months1 
 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 8: Effects of mango, rosiglitazone, and fenofibrate on plasma adiponectin 
concentrations of mice fed high fat (HF) diet for two months1 
 
 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 9: Effects of mango, rosiglitazone, and fenofibrate on relative mRNA of acetyl-
CoA carboxylase alpha (ACCα) in the liver of mice fed high fat diet (HF) for two months1 
 
 
1Bars are mean ± SE, n=6/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
 
 
 
 
 
 70
Figure 10: Effects of mango, rosiglitazone, and fenofibrate on relative mRNA of acyl-
coenzyme A oxidase 1 (ACOX1) in the liver of mice fed high fat (HF) diet for two 
months1  
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 11: Effects of mango, rosiglitazone, and fenofibrate on relative mRNA of 
medium-chain acyl dehydrogenase (MCAD) in the liver of mice fed high fat (HF) diet for 
two months1  
 
 
 
 
1Bars are mean ± SE, n=6/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 12: Effects of mango, rosiglitazone, and fenofibrate on relative mRNA of fatty 
acid transporter protein 5 (FATP5) in the liver of mice fed high fat diet (HF) for two 
months1  
 
 
1Bars are mean ± SE, n=6/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 13: Effects of mango, rosiglitazone, and fenofibrate on relative mRNA of 
lipoprotein lipase (LPL) in the liver of mice fed high fat (HF) diet for two months1  
 
 
 
 
1Bars are mean ± SE, n=6/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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Figure 14: Effects of mango, rosiglitazone and fenofibrate on relative mRNA level of 
peroxisome proliferator-activated receptor alpha (PPARα) in the liver of mice fed high 
fat (HF) diet for two months1  
 
 
 
 
1Bars are mean ± SE, n=8/group; Bars that do not share the same letters are significantly (P<0.05) 
different from each other.  
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CHAPTER V 
 
CONCLUSION 
 
This study investigated the effect of two doses of freeze-dried mango on body 
composition and blood glucose and lipids in a mouse model of high fat diet-induced 
obesity. Moreover, the effects of mango were compared to that of fenofibrate and 
rosiglitazone, known PPAR agonists. This animal study lasted for about eight weeks and 
the experiment duration is slightly shorter than other studies fed animals with high fat 
diet [238-239]; however the effects of treatments had shown already in a short period. 
In this study, we did not observe differences in weekly and final body weights 
among the treatment groups. This is likely due to the mice in the normal diet having 
significantly higher food intake than those in the high fat diet since mice were fed ad 
libitum. Moreover, all groups fed the high fat diet groups had similar food intake. Despite 
similar final body weights among the groups, there were differences in body composition, 
specifically fat mass and percent body fat. No difference in lean mass was observed. Fat 
mass and percent body fat was highest in the high fat group and the two doses of mango 
had comparable effect to that of rosiglitazone and fenofibrate in modulating body fat, 
which illustrated the benefit of mango supplements in reducing body fat. To our 
knowledge, this is the first study demonstrating the effectiveness of mango in reducing 
body fat.   
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The findings of our study that fenofibrate prevents adiposity is consistent with 
other animal studies [32, 240-241]. This effect of fenofibrate on adiposity is attributed to 
its role in regulating the synthesis and clearance of lipoprotein [161] and energy 
dissipation by induction of uncoupling protein in the liver mitochondria [242]. In our 
study, treatment with rosiglitazone reduced the weight of adipose tissue to the control 
group. This finding is consistent with the pleiotropic effects of TZDs modulating visceral 
fat while increasing subcutaneous fat [243]. Rosiglitazone is a known PPAR-γ agonist 
and is responsible for cell differentiation in adipose tissue [244] which may partly explain 
the decrease in adipose tissue mass observed in this study. If cell differentiation is limited 
by rosiglitazton, the growth of adipose tissue might be restricted.  
 Our study showed that 1% and 10% mango supplementation, similar to 
rosiglitazone and fenofibrate, reduced adipose tissue mass to that of the mice fed normal 
rodent diet (AIN-93M). The mechanism by which mango reduces fat mass may partly be 
due to its effect on upregulating the gene expression of aP2. Adipocyte protein 2 (aP2) is 
a marker of terminal adipocyte differentiation and involved in free fatty acid transport 
and shunting within the cell [245-246]. PPAR-γ agonists such as rosiglitazone upregulate 
the expression of aP2, a PPAR-γ target gene [247]. Our findings show that the aP2 gene 
expression tended (P=0.0598) to be elevated with rosiglitazone treatment (three times 
higher than the high fat diet fed mice not receiving rosiglitazone), however, a relatively 
low dose of rosiglitazone as was used in our study may be sufficient to augment the 
induction of lean phenotype as seen by Kuda and colleagues [248]. However, a ten fold 
higher dose of rosiglitazone has been shown to promote obesity, as observed in most 
studies with mice [249-250]. The reduced aP2 expression in the high fat diet fed animals 
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may be an adaptive response of the adipose tissue to limit further expansion of fat 
storage. The effects of mango and rosiglitazone on adipose mass may be by modulating 
the expression of a critical nuclear transcription factorthat can trigger the entire process 
of adipocyte differentiation.  However, this is speculative and needs to be further 
explored. 
 In addition to its role in adipocyte differentiation, aP2 is also linked to 
inflammation and metabolic syndrome [246]. Circulating aP2 is correlated with insulin 
resistance and dyslipidemia in human studies [251-252]. aP2 deficiency is believed to 
promote insulin resistance in high fat diet induced obesity mouse model [253].  
Liver weight and changes in expression of genes in the liver regulated by 
fenofibrate demonstrated the effectiveness of the dose of fenofibrate used in this study. 
Mice receiving fenofibrate had the highest liver weight among all the treatment groups, 
which is consistent with the findings in rats and mice [254]. Fenofibrate induces 
peroxisome proliferation in the liver which contributed to the increase in liver weight. 
Peroxisomes are organelles that contain many enzymes involved in fatty acid degradation 
[255] and PPAR-α agonist activates genes encoding these enzymes during dimerization 
with RXR [42, 256]. Low dose mango did not cause an increase in liver weight as seen 
with fenofibrate, while the high dose mango group had an intermediate effect on liver 
weight.  
Glucose tolerance tests demonstrated that freeze-dried mango at l% dose 
exhibited glucose lowering properties in our animal model. This result is more 
pronounced than the one obtained from the rosiglitazone group, a known glucose-
lowering agent. As a comparison, the 10% dose mango is similar to the rosiglitazone 
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group, but not as impressive as the 1% dose in lowering blood glucose. In addition to the 
glucose tolerance test, plasma glucose obtained at the end of the study confirmed the 
glucose-lowering properties of mango. Similar to the findings of the glucose tolerance 
test, the low dose mango had the most effect in reducing plasma glucose. This unique 
glucose lowering property of mango may be attributed to the increasing stimulation of 
pancreatic cells to secrete insulin [206] or the suppression of intestinal absorption of 
glucose [257]. To our knowledge, only three studies have been conducted that 
investigated the glucose lowering properties of mango and these studies have been 
limited to the extract of stem bark [207] or leaves [258]. The aqueous extract of mango 
leaves prevented hyperglycemia in STZ-induced diabetic rats [258]. Our findings are the 
first to demonstrate the effectiveness of mango pulp in modulating hyperglycemia 
induced by high fat diet. 
There were no significant differences in the mRNA expression of GLUT4. 
Translocation of GLUT4 to the cell membrane promotes glucose uptake resulting to 
lower blood glucose concentrations [179]. The mechanism of how mango exactly 
performs glucose lowering effects is not clear at this time. Mango may affect genes 
involved in hepatic glycogenesis and gluconeogenesis and not necessarily uptake and 
genes involved in these pathways should be examined in future studies. 
The component of mango responsible for this positive effect on glucose is not 
known at this time. In addition to the phenolic content of mango, a component that may 
have contributed to this glucose-lowering property of mango is dietary fiber. The mango 
used in this study contains approximately 4% dietary fiber. Dietary fiber has been shown 
to lower blood glucose level in laboratory animals [259] and in humans [260]. For 
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example, dietary fiber fractions from the plant, Trigonella foenum graecum, lowered 
blood glucose in a rat model of type 2 diabetes by interfering with the digestion of 
sucrose [261]. Similarly, cereal fiber lowered glucose level in diabetics [262]. 
The antioxidant content of mango may also help in reducing oxidative stress and 
lowering complications of diabetes. Mango is a significant source of the antioxidants β-
carotene and C [23]. Increased amount of fatty acids and modified lipoproteins can 
induce oxidative stress as a result of inflammatory responses, and the production of free 
radicals promote the complications associated with type 2 diabetes [263]. Several studies 
have reported that depletion of antioxidants (i.e; tocopherols, carotene, ascorbic acids, 
lycopene) is involved in cardiovascular and diabetes complications [264-267]. These 
antioxidants have inhibitory effect on ROS generation by suppressing the activity of ROS 
producing enzymes such as xanthine oxidase, cyclooxygenase, lipoxygenase, microsomal 
monooxygenase, glutathione-S-transferase, mitochondrial succinoxidase, NADH oxidase 
[268]. The effect of mango in reducing oxidative stress needs to be further explored.  
In addition to lowering glucose, mango had moderate effects on plasma total 
cholesterol in this animal model. Mice receiving the two doses of mango or rosiglitazone 
had similar total cholesterol to those receiving the normal diet. However, plasma total 
cholesterol of the mango group was not statistically different from those receiving the 
high fat diet. Interestingly, fenofibrate produced an increase in plasma total cholesterol 
and has no effect on triglycerides, which is contradictory to the findings of some earlier 
studies [168, 170, 176-177].  Fenofibrate is a known hypolipidemic drug that has been 
used to manipulate lipid metabolism since 1980 [160]. It activates lipoprotein lipase to 
reduce the generation of triglycerides in the liver in mice [175-176].  
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The fenofibrate group also showed the highest plasma HDL-C concentration 
which is consistent with earlier findings [170]. Moreover, the fenofibrate group exhibited 
significantly higher liver gene expression of ACCα, ACOX1, FATP5, LPL and MCAD, 
again consistent with other studies [155, 241]. Changes in the gene expression in the liver 
explain the observed effect on lipids by fenofibrate. Whether mango acts similarly as 
fenofibrate in modulating lipids is not clear at this time. 
Futher studies may need to focus on genes involved in glucose metabolism that 
could investigate the hypoglycemic effect of mango. Overall, low dose mango was better 
than the glucose lowering drug, rosiglitazone, in modulating blood glucose concentration 
due to high fat diet. Moreover, mango similar to rosiglitazone favorably alters body 
composition by reducing % body fat without affecting lean mass. Human studies need to 
be conducted to confirm our findings. 
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10% mango, and fenofibrate and rosiglitazone groups. Mice receiving 1% mango groups 
had the lowest area under the curve after a glucose tolerance test. The two doses of 
mango significantly reduced plasma non-esterified fatty acids to the level of normal diet 
group. 
 
Findings and Conclusions: Supplementation with 1% mango for 8 weeks was the most 
effective in modulating glucose and lipid levels due to high fat diet. Our findings suggest 
that incorporation of mango in the diet reduces CVD risk factors in this animal model and 
warrants further investigation in humans.  
 
 
 
 
 
 
 
 
 
 
